




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

COVID-19 dynamics and immune response: Linking within-host and between-host dynamics

Matthew O. Adewole, Taye Samuel Faniran, Farah A. Abdullah, Majid K.M. Ali



PII: S0960-0779(23)00623-9
DOI: <https://doi.org/10.1016/j.chaos.2023.113722>
Reference: CHAOS 113722

To appear in: *Chaos, Solitons and Fractals*

Received date: 2 February 2023
Revised date: 26 April 2023
Accepted date: 13 June 2023

Please cite this article as: M.O. Adewole, T.S. Faniran, F.A. Abdullah et al., COVID-19 dynamics and immune response: Linking within-host and between-host dynamics. *Chaos, Solitons and Fractals* (2023), doi: <https://doi.org/10.1016/j.chaos.2023.113722>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Ltd.

COVID-19 Dynamics and Immune Response: Linking Within-Host and Between-Host Dynamics

Matthew O. Adewole

*School of Mathematical Sciences, Universiti Sains Malaysia, Malaysia
Department of Computer Science and Mathematics, Mountain Top University,
Prayer City, Ogun State, Nigeria*

Taye Samuel Faniran

*Laboratory de Mathematiques de Besancon, University of Franche-Comte, France
Department of Computer Science, Lead City University, Ibadan, Nigeria*

Farah A. Abdullah**

School of Mathematical Sciences, Universiti Sains Malaysia, Malaysia

Majid K. M. Ali**

School of Mathematical Sciences, Universiti Sains Malaysia, Malaysia

Abstract

The global impact of COVID-19 has led to the development of numerous mathematical models to understand and control the pandemic. However, these models have not fully captured how the disease's dynamics are influenced by both within-host and between-host factors. To address this, a new mathematical model is proposed that links these dynamics and incorporates immune response. The model is compartmentalized with a fractional derivative in the sense of Caputo-Fabrizio, and its properties are studied to show a unique solution. Parameter estimation is carried out by fitting real-life data, and sensitivity analysis is conducted using various methods. The model is then numerically implemented to demonstrate how the dynamics within infected hosts drive human-to-human transmission, and various intervention strategies are compared based on the percentage of averted deaths. The simulations suggest that a combination of medication to boost the immune system, prevent infected cells from producing the virus, and adherence to COVID-19 protocols is necessary to control the spread of the virus since no single intervention strategy is sufficient.

Keywords: COVID-19; Fractional derivatives; Fixed point; Sensitivity analysis;

*Corresponding author

**Corresponding author

Email addresses: farahaini@usm.my (Farah A. Abdullah), majidkhanmajaharali@usm.my (Majid K. M. Ali)

Multi-Scale

2020 MSC: 92B05; 92C37; 92D30; 34A08

1 Introduction

2 The Coronavirus disease, globally called COVID-19, started in Wuhan, China
3 and has affected millions of people across the globe [1]. The virus that causes
4 COVID-19 is SARS-CoV-2, belonging to the family Coronaviridae and in the
5 Nidovirales order [2]. The most common symptoms of COVID-19 include fever,
6 cough, and other flu-like symptoms such as fatigue, chills, and sore throat.
7 Critically ill patients can develop severe pneumonia, sometimes acute respiratory
8 distress, which can lead to multiple organ failure and death. [3]. Some of the
9 factors that complicate COVID-19 control are the individual's immune response
10 to SARS-CoV-2 and long period of incubation [4]. For more details as regards
11 the diagnosis, symptoms, fatality rate etc. of SARS-CoV-2, see [3, 5–8].

12 Our focus here is to use a mathematical model to better understand the
13 dynamics and control COVID-19. Several mathematical models have been
14 proposed to study the epidemiology of COVID-19. For instance, see [8–17].

15 Monda & Khajanchi [18] developed a compartmental model of COVID-19 in
16 India and showed that disease transmission rate has an impact on controlling the
17 spread of the disease. Zenebe et al [19] proposed and validated a mathematical
18 model for the transmission dynamics of COVID-19, using the COVID-19 infected
19 data reported from March 13, 2020 to July 31, 2021, in Ethiopia. Their results
20 showed that the spread of COVID-19 can be controlled by minimizing contact
21 rate of infected people and increasing quarantine of exposed individuals. The
22 results and conclusions of the articles [8–19] seem interesting however only the
23 epidemiology of the virus was considered while the immunology aspect was
24 neglected.

25 The dynamics of SARS-CoV-2 in human host has been mathematically
26 studied by few authors. For instance in [20], the authors studied an in-host
27 model that gave the influence of effector T-cell to the behaviour of SARS-CoV-2
28 within human host. Their results suggested that SARS-CoV-2 may replicate
29 fast enough to overcome T cells response and cause infection. Mathematical
30 analysis of the model in [21] was analyzed in [22]. It was biologically gathered
31 that for the basic reproduction number to be less than unity, infection needs
32 to be cleared from a human body. Recently, the authors in [23] proposed a
33 within-host mathematical model of SARS-CoV-2 dynamics incorporating innate
34 and adaptive immune responses. In their results, it was suggested that blocking
35 the infected cells from producing the virus can be an effective control measure.

36 Animal models are often used for experimental trials, while developing
37 antiviral drugs. Thus in [24], mathematical models and experimental data were
38 used to characterize the in-host SARS-CoV-2 dynamics in ferrets (animal hosts).
39 It was reported, by analysis and simulations, that ferrets can be an appropriate
40 animal model for SARS-CoV-2 dynamics in human hosts. Immune response
41 has a significant impact on the dynamics of SARS-CoV-2 within a human host

42 however, the data fitting in [24] did not support the need to include immune
43 response in the model. This is a significant gap. A within-host and aerosol
44 mathematical model was proposed in [25] and used to determine the relationship
45 between viral kinetics in the aerosols as well as the upper respiratory track, and
46 new transmissions in golden hamsters challenged with SARS-CoV-2. The authors
47 reported sex-based differences in the dynamics of the virus - the within-host
48 basic reproductive number is less than one in all female hamsters while basic
49 reproductive number is above one in all male hamsters.

50 In this article, we propose a model which links the dynamics of the disease
51 within a host with the dynamics of the disease between hosts. This kind of
52 model is known as multiscale model and has been extensively used to study
53 the transmission dynamics of infectious diseases [26–31]. However, the use of
54 multiscale model to study the dynamics of SARS-CoV-2 is very rare in literature.
55 The advantage of multiscale approach is that it gives more comprehensive insights
56 to the understanding the spread of a disease at different scales [26].

57 Bellomo et al [32] proposed a multiscale modeling of COVID-19 pandemic and
58 presented further development of the model developed by [33]. They incorporated
59 the dynamics of mutations into new variants and showed that the onset of a new
60 variant that is more aggressive than the primary virus, generates a progressive
61 prevalence of the variant over the firstly appeared virus. Wang et al [34]
62 developed a multiscale model to study the coupled within-host and between-host
63 dynamics of COVID-19. Explicit analysis was carried out, in terms of local and
64 global dynamics of fast, slow and full systems, which includes both forward and
65 backward bifurcations. It was concluded that viral treatment can delay, but
66 not prevent, the onset of disease. Between host and within host dynamics of
67 pathogen evolution with application to SARS-CoV-2 was presented in [35]. The
68 within-host dynamics was modelled using random walk while an SIR model was
69 used for inter-host dynamics. This allowed for consideration of multiple hosts.
70 However, the random walk model is not suitable for modeling interventions
71 like vaccination or social distancing. Therefore, the article did not discuss
72 intervention strategies or the impact of memory processes. Additionally, the
73 epidemiological dynamics of COVID-19 are more complex than the SIR model
74 used in the article.

75 We contribute to the existing body of works by proposing and studying a
76 fractional mathematical model which links the between-host and within-host
77 models to investigate the dynamics of SARS-CoV-2 replication inside a human
78 host and COVID-19 spread outside a human host. The main reasons for using
79 a differential operator with fractional order are that many systems (including
80 disease dynamics) are influenced by memory, history, or non-local effects, which
81 can be difficult to model with integer order derivatives [36]. The fractional
82 differential operator for the constructed model is taken in the Caputo-Fabrizio
83 sense because it is non-local, non-singular and has a fading memory [37]. A
84 fractional differential operator with fading memory is used with the hypothesis
85 that the dynamics of SARS-CoV-2 depends on the recent past occurrences but
86 not on the distant past.

87 Many studies have reported that immune response is important in modeling

88 virus infections, see [20, 38, 39] and the references therein. T-cells (helper
 89 T-cells and cytotoxic T-cells in particular) play a significant role in the fight
 90 against pathogens and the risk of developing autoimmunity or overwhelming
 91 inflammation [39]. In within-host dynamics, helper T-cells activate other cells
 92 (such as B cells) to secrete antibodies that kill the invading virus while cytotoxic
 93 T-cells can kill virally infected cells [22, 39–41]. Helper and cytotoxic T-cells
 94 are parts of adaptive immune response. Innate immunity also helps to attack
 95 foreign bodies in human body. While adaptive immunity is specific in its actions,
 96 innate immunity is general and non-specific, it is also the first line of defence
 97 against pathogens [42, 43]. Innate and adaptive immune responses are therefore
 98 incorporated into our model and their impacts on the dynamics of SARS-CoV-2
 99 are investigated. These were not considered in [32–35]. We include in our model,
 100 the populations of natural killer cells, B-cells and cytotoxic T-cells with the
 101 assumption that the transmission rate is a function of the viral load. Qualitative
 102 properties of our model is given after which some parameters of the model are
 103 estimated by fitting the model to real-life data. Simulations are then carried out
 104 to investigate the influence of each parameter on the dynamics of the disease
 105 and various intervention strategies are suggested.

106 The rest of this article is organized as follows: A deterministic model is
 107 formulated and analyzed in Section 2. It was shown in Section 3 that the model
 108 has a unique solution while the disease free stationary solution of the model
 109 is analyzed in Section 3. Parameter estimation, sensitivity analysis and other
 110 simulations are done in Section 5. The work is concluded in Section 6.

111 2. Model Description and Formulation

112 The between-host subsystem is divided into five compartments: Susceptible
 113 human (H_S), Exposed human (H_E), Infectious human (H_I) (asymptomatic and
 114 symptomatic), Quarantined human (H_Q) and Recovered human (H_R).

115 The following assumptions were made:

- 116 (i) There is no vertical transmission of the virus;
- 117 (ii) The transmission of the virus is only by coming in contact with an infectious
 118 individual;
- 119 (iii) There is no immigration of infectious individuals;
- 120 (iv) The dynamics of the disease is independent of weather;
- 121 (v) Humans die naturally at a rate μ .

122 A new recruit enters the susceptible human population at a rate Λ . It was
 123 reported in [44] that the transmission of SARS-CoV-2 is directly connected to
 124 the viral load in infectious individuals. It is therefore assumed that transmission
 125 of the virus depends on the average viral load per infected individual. Susceptible

126 human comes in contact with an infectious human who sheds virus and becomes
 127 infected at a rate $\beta(V)$.

$$D_t^\theta H_S = \Lambda - \beta(V)H_I H_S - \mu H_S + \tau H_R. \quad (2.1)$$

128 Where $0 \leq \beta(V) \leq \beta_0, \forall V \in [0, \infty), \beta_0 \in \mathbb{R}$. An exposed individual becomes
 129 infectious at a progression rate σ , becomes detected and quarantined at a rate
 130 π_E .

$$D_t^\theta H_E = \beta(V)H_I H_S - (\sigma + \mu + \pi_E)H_E. \quad (2.2)$$

131 An infectious individual die due to infection at a rate δ_I , detected and
 132 quarantined at a rate π_I , and recover at a rate ρ_I .

$$D_t^\theta H_I = \sigma H_E - (\mu + \delta_I + \pi_I + \rho_I)H_I. \quad (2.3)$$

133 Quarantined human die as a result of COVID-19 at a rate δ_Q and recovered
 134 individuals lose their immunity and become susceptible after a period of $\frac{1}{\tau}$.

$$D_t^\theta H_Q = \pi_E H_E + \pi_I H_I - (\mu + \rho_Q + \delta_Q)H_Q. \quad (2.4)$$

$$D_t^\theta H_R = \rho_I H_I + \rho_Q H_Q - (\mu + \tau)H_R. \quad (2.5)$$

136 Following [22, 23, 45, 46], the within host subsystem consists of susceptible
 137 epithelial cell population (E_S), latently infected epithelial cells (E_L), infectious
 138 epithelial cells (E_I), SARS-CoV-2 virus in the biological environment (V), natural
 139 killer cells (K), B cells (B) and cytotoxic T-cells (T).

140 Viral load within an infected individual is generated following intake of SARS-
 141 CoV-2 through transmission from an infectious individual. When transmission
 142 takes place, the population of susceptible individuals decreases by 1 while the
 143 population of infected individuals increases by one. Thus following [26], we
 144 assume that when a susceptible human contract SARS-CoV-2 virus, there is a
 145 transition given by

$$(H_S(t), H_E(t) + H_I(t)) \rightarrow (H_S(t) - 1, H_E(t) + H_I(t) + 1).$$

146 Therefore, the average rate of intake of SARS-CoV-2 virus by a single susceptible
 147 human host is modelled by

$$\frac{\beta(V)\eta H_I (H_S - 1)}{H_E + H_I + 1},$$

148 leading to one infected human host. This means that the average viral load
 149 in an infected human increases at a rate $\frac{\beta(V)\eta H_I (H_S - 1)}{H_E + H_I + 1}$ where η represents the
 150 average viral load intake by a susceptible individual who comes in contact with
 151 an infectious individual.

152 Helper T-cells promote the production of virus-specific antibodies by acti-
 153 vating T-dependent B-cells [43, 47]. Let κVB represent the local interaction
 154 dynamics of the virus V with B cells (B). Due to this interaction, virus particles

155 are reduced at the rates κ . Also, infectious epithelial cells produce virus into the
 156 biological environment at a rate a . We thus have

$$D_t^\theta V = \frac{\beta(V)\eta H_I(H_S - 1)}{H_E + H_I + 1} + aE_I - \kappa VB - mV. \quad (2.6)$$

157 Susceptible epithelial cells (E_S) become latently infected (E_L) by free virus
 158 in the biological environment at a rate ε . d represents death rate while λ is the
 159 regeneration rate of susceptible epithelial cells.

$$D_t^\theta E_S = \lambda - \varepsilon E_S V - dE_S. \quad (2.7)$$

160 Latently infected epithelial cells (E_L) become infectious after $\frac{1}{\phi}$ days and
 161 also die naturally at a rate d . When a cell becomes infected with the virus, it
 162 becomes a target for natural killer cells and cytotoxic T lymphocytes which
 163 attack and kill the infected cells [22, 39–41, 43, 47]. Let the γ_1 and γ_2 be the
 164 rates at which natural killer cells and cytotoxic T lymphocytes, respectively,
 165 interact and kill infected epithelial cells. Then we have

$$D_t^\theta E_L = \varepsilon E_S V - \gamma_1 K E_L - \gamma_2 T E_L - (\phi + d)E_L, \quad (2.8)$$

$$D_t^\theta E_I = \phi E_L - \gamma_1 K E_I - \gamma_2 T E_I - dE_I. \quad (2.9)$$

167 For the dynamics of natural killer cells, B-cells and cytotoxic T-cells, we have
 168 the following equations,

$$D_t^\theta K = \lambda_K \left(1 + \frac{\xi V}{1 + V}\right) - \varpi_K K, \quad (2.10)$$

$$D_t^\theta B = \frac{\alpha_B V}{1 + V} - \varpi_B B, \quad (2.11)$$

$$D_t^\theta T = \frac{\alpha_T V}{1 + V} - \varpi_T T. \quad (2.12)$$

169 λ_K represents the natural recruitment rate of natural killer cells while $\varpi_K, \varpi_B, \varpi_T$
 170 represent the natural clearance rates of natural killer cells, B-cells and cytotoxic
 171 T-cells respectively. It is assumed that the recruitment rate of natural killer
 172 cells increases with the inversion of the virus. B-cells and cytotoxic T-cells are
 173 adaptive immune responses and only respond when there is a foreign inversion
 174 by virus [40, 42, 43]. Therefore their recruitment depends on viral inversion. We
 175 denote by α_B and α_T the maximum proliferations in response to the presence
 176 of virus particles. Figure 2.1 describes the model diagrammatically. Putting
 177 (2.1)–(2.12) together, we have the multiscale model below




Figure 2.1: Flow diagram of the mathematical model linking within-host and between-host dynamics of SARS-CoV-2

Table 1: Description of state variables of between-host and within-host COVID-19 model

Variables	Description
H_S	Susceptible human
H_E	Exposed human
H_I	Infectious human
H_Q	Quarantined human
H_R	Recovered human
V	Average viral load within a single infected human
E_S	Susceptible epithelial cells
E_L	Latently infected epithelial cells
E_I	Infectious epithelial cells
K	Killer T-cells
B	B-cells
T	Cytotoxic T-cells

Table 2: Summary of the parameters

Parameter	Meaning	Value	Reference
Λ	Recruitment rate for human population	$N_0\mu$ individual day ⁻¹	
β	Effective transmission rate per infectious individual per time	1.70×10^{-7} individual ⁻¹ day ⁻¹	Data fitting
τ	Loss of immunity rate	$1/76$ day ⁻¹	[48]
σ	Progression rate at which exposed individuals become infectious	$1/8$ day ⁻¹	[19, 49, 50]
π_E	Quarantine rate of H_E	0.761 day ⁻¹	Data fitting
π_I	Quarantine rate of H_I	0.90 day ⁻¹	Data fitting
δ_I	Disease-induced death rate for undetected infectious individuals	0.015 day ⁻¹	[51]
δ_Q	Disease-induced death rate for quarantined individuals	1.64×10^{-5} day ⁻¹	Data fitting
ρ_I	Recovery rate of H_I	$1/15$ day ⁻¹	[52, 53]
ρ_Q	Recovery rate of H_Q	0.101 day ⁻¹	Estimated [54]
μ	Natural death rate of human	$(43.5 \text{ year})^{-1}$	[55]
η	Average viral load intake by a susceptible individual who comes in contact with an infectious individual	2.15 copies ml ⁻¹	Data fitting
a	Production rate of SARS-CoV-2	12 copies ml ⁻¹ cell ⁻¹ day ⁻¹	[34]
κ	Killing rate of the virus by B-cell per time	1.0×10^{-5} cell ⁻¹ day ⁻¹	[23]
λ	Recruitment rate of E_S	$dE_S(0)$ cells day ⁻¹	[56]
ε	Rate at which E_S are infected by SARS-CoV-2	1.12×10^{-5} ml copy ⁻¹ day ⁻¹	Data fitting
d	Natural death rate of epithelia cells	10^{-3} day ⁻¹	[57]
γ_1	Killing rate of infected epithelia cells by natural killer cell	5.74×10^{-5} cell ⁻¹ day ⁻¹	[58]
γ_2	Killing rate of infected epithelia cells by cytotoxic T-cell	4.84×10^{-5} cell ⁻¹ day ⁻¹	Data fitting
ϕ	Transition rate from E_L to E_I	0.60 day ⁻¹	Data fitting
α_T	Activation rate of cytotoxic T-cells	1.6×10^3 cells day ⁻¹	Assumed
α_B	Activation rate of B-cells	1.6×10^3 cells day ⁻¹	Assumed
λ_K	Constant regeneration rate of natural killer cells	1.6×10^3 cells day ⁻¹	[59]
ϖ_K	Natural death rate for natural killer cells	4.12×10^{-2} day ⁻¹	[60]
ϖ_B	Natural death rate for B-cells	ϖ_K	Assumed
ϖ_T	Natural death rate for cytotoxic T-cells	0.1 day ⁻¹	[57]
φ	Half saturation constant for viral shedding	0.759 copy ml ⁻¹	Estimated [61]
m	Natural viral clearance rate from biological environment	0.699 day ⁻¹	Data fitting
ξ	Influence of viral load on regeneration rate of natural killer cells	0.688	Data fitting
ψ	Influence of viral load on transmission	0.598	Data fitting

$$D_t^\theta H_S = \Lambda - \beta(V)H_I H_S - \mu H_S + \tau H_R, \quad (2.13)$$

$$D_t^\theta H_E = \beta(V)H_I H_S - (\sigma + \mu + \pi_E)H_E, \quad (2.14)$$

$$D_t^\theta H_I = \sigma H_E - (\mu + \delta_I + \pi_I + \rho_I)H_I, \quad (2.15)$$

$$D_t^\theta H_Q = \pi_E H_E + \pi_I H_I - (\mu + \rho_Q + \delta_Q)H_Q, \quad (2.16)$$

$$D_t^\theta H_R = \rho_I H_I + \rho_Q H_Q - (\mu + \tau)H_R, \quad (2.17)$$

$$D_t^\theta V = \frac{\beta(V)\eta H_I (H_S - 1)}{H_E + H_I + 1} + aE_I - \kappa V B - mV, \quad (2.18)$$

$$D_t^\theta E_S = \lambda - \varepsilon E_S V - dE_S, \quad (2.19)$$

$$D_t^\theta E_L = \varepsilon E_S V - \gamma_1 K E_L - \gamma_2 T E_L - (\phi + d)E_L, \quad (2.20)$$

$$D_t^\theta E_I = \phi E_L - \gamma_1 K E_I - \gamma_2 T E_I - dE_I, \quad (2.21)$$

$$D_t^\theta K = \lambda_K \left(1 + \frac{\xi V}{1 + V}\right) - \varpi_K K, \quad (2.22)$$

$$D_t^\theta B = \frac{\alpha_B V}{1 + V} - \varpi_B B, \quad (2.23)$$

$$D_t^\theta T = \frac{\alpha_T V}{1 + V} - \varpi_T T. \quad (2.24)$$

178 Model (2.13)–(2.24) has the following initial conditions:

$$179 H_S(0) = HS0 > 0, H_E(0) = HE0 \geq 0, H_I(0) = HI0 \geq 0, H_Q(0) = HQ0 \geq 0,$$

$$180 H_R(0) = HR0 \geq 0, V(0) = V0 > 0, E_S(0) = ES0 > 0, E_L(0) = EL0 \geq 0,$$

$$181 E_I(0) = EI0 \geq 0, K(0) = K0 > 0, B(0) = B0 \geq 0, T(0) = T0 \geq 0.$$

182 All parameters are non-negative for all $t \geq 0$ and are as defined in Table
183 2 while the fractional derivative is understood to be in Caputo-Fabrizio (CF)
184 sense. We have the following definition (cf [37]):

185 **Definition 2.1.** For a given function $g \in H^1(a, b)$, $b > a$, the Caputo-Fabrizio
186 (CF) fractional derivative is defined as

$$D_t^\theta g(t) = \frac{\mathbb{M}(\theta)}{1 - \theta} \int_a^t g'(s) \exp\left[-\theta \frac{t-s}{1-\theta}\right] ds. \quad (2.25)$$

187 where $\mathbb{M}(\theta)$ is a normalization functions satisfying $\mathbb{M}(0) = \mathbb{M}(1) = 1$.

188 Without losing generality, we take $\mathbb{M}(\theta) = 1$, where $\theta \in (0, 1)$ represents the
189 fractional order index. The fractional integral corresponding to (2.25) is defined
190 in [62] as

$$I_t^\theta g(t) = \frac{2(1-\theta)}{2-\theta} g(t) + \frac{2\theta}{2-\theta} \int_0^t g(s) ds, \quad t \geq 0, \theta \in (0, 1). \quad (2.26)$$

191 The dimension of the right side of model (2.13)–(2.24) is day^{-1} while the
192 fractional operator on the left has dimension $\text{day}^{-\theta}$. To address this prob-
193 lem of dimensional mismatch, we use the approach in [63], in which case the
194 normalization parameter is taken as 1.

195 **3. Existence and uniqueness of solutions to the model**

196 In this section, we show that model (2.13)–(2.24) with the initial condition
 197 has a unique solution. For convenience, we define

$$X(t) = \begin{bmatrix} H_S(t) \\ H_E(t) \\ H_I(t) \\ H_Q(t) \\ H_R(t) \\ V(t) \\ E_S(t) \\ E_L(t) \\ E_I(t) \\ K(t) \\ B(t) \\ T(t) \end{bmatrix} \quad \text{and } \chi(t, X(t)) = \begin{bmatrix} \Lambda - \beta(V) H_I H_S - \mu H_S + \tau H_R \\ \beta(V) H_I H_S - (\sigma + \mu + \pi_E) H_E \\ \sigma H_E - (\mu + \delta_I + \pi_I + \rho_I) H_I \\ \pi_E H_E + \pi_I H_I - (\mu + \rho_Q + \delta_Q) H_Q \\ \rho_I H_I + \rho_Q H_Q - (\mu + \tau) H_R \\ \frac{\beta(V) \eta H_I (H_S - 1)}{H_E + H_I + 1} + a E_I - \kappa V B - m V \\ \lambda - \varepsilon E_S V - d E_S \\ \varepsilon E_S V - \gamma_1 K E_L - \gamma_2 T E_L - (\phi + d) E_L \\ \phi E_L - \gamma_1 K E_I - \gamma_2 T E_I - d E_I \\ \lambda_K \left(1 + \frac{\xi V}{1 + V} \right) - \varpi_K K \\ \frac{\alpha_B V}{1 + V} - \varpi_B B \\ \frac{\alpha_T V}{1 + V} - \varpi_T T \end{bmatrix}.$$

198 **Theorem 3.1.** $\chi(t, X(t))$ satisfies the Lipschitz condition

$$\|\chi(t, X_1(t)) - \chi(t, X_2(t))\| \leq \Delta \|X_1(t) - X_2(t)\|. \quad (3.1)$$

199 Furthermore, if there exists $t_0 > 0$ such that

$$\left(\frac{2(1-\theta)}{2-\theta} + \frac{2\theta}{2-\theta} t_0 \right) \Delta < 1, \quad (3.2)$$

200 then the fractional initial value problem (2.13)–(2.24) admits a unique solution
 201 on the interval $[0, t_0]$.

202 *Proof.* Clearly, $H_S, H_E, H_I, H_Q, H_R, V, E_S, E_L, E_I, K, B, T$ are bounded
 203 functions and there exist $\aleph_i > 0$, ($i = 1, \dots, 12$) such that $\|H_S(t)\| \leq \aleph_1$,
 204 $\|H_E(t)\| \leq \aleph_2$, $\|H_I(t)\| \leq \aleph_3$, $\|H_Q(t)\| \leq \aleph_4$, $\|H_R(t)\| \leq \aleph_5$, $\|V(t)\| \leq \aleph_6$,
 205 $\|E_S(t)\| \leq \aleph_7$, $\|E_L(t)\| \leq \aleph_8$, $\|E_I(t)\| \leq \aleph_9$, $\|K(t)\| \leq \aleph_{10}$, $\|B(t)\| \leq \aleph_{11}$,
 206 $\|T(t)\| \leq \aleph_{12}$. Where $\|\cdot\|$ denotes the maximum norm.

207 Now consider kernel χ_1 . Let H_S^1, H_S^2 be any two functions (with other
 208 variables as constant), then

$$\begin{aligned} \|\chi_1(t, H_S^1) - \chi_1(t, H_S^2)\| &= \|\beta(V) H_I (H_S^1 - H_S^2) + \mu (H_S^1 - H_S^2)\|, \\ &\leq \|\beta_0 H_I (H_S^1 - H_S^2) + \mu (H_S^1 - H_S^2)\|, \\ &\leq (\beta_0 \aleph_3 + \mu) \|H_S^1 - H_S^2\|. \end{aligned}$$

209 Let H_I^1, H_I^2 be any two functions (with other variables as constant), then

$$\begin{aligned} \|\chi_1(t, H_I^1) - \chi_1(t, H_I^2)\| &= \|\beta(V) H_S (H_I^1 - H_I^2)\|, \\ &\leq \|\beta(1 + \psi) H_S (H_I^1 - H_I^2)\|, \\ &\leq \beta_0 \aleph_1 \|H_I^1 - H_I^2\|. \end{aligned}$$

210 Let H_R^1, H_R^2 be any two functions (with other variables as constant), then

$$\|\chi_1(t, H_R^1) - \chi_1(t, H_R^2)\| = \tau \|H_R^1 - H_R^2\|.$$

211 Finally, let V^1, V^2 be any two functions (with other variables as constant), then

$$\begin{aligned} \|\chi_1(t, V^1) - \chi_1(t, V^2)\| &= \|H_S H_I (\beta(V^1) - \beta(V^2))\|, \\ &\leq |\beta'(\Gamma)| \aleph_1 \aleph_3 \|V^1 - V^2\|. \end{aligned}$$

212 Use is made of mean value theorem to obtain the above, where $\Gamma \in (V^1, V^2)$.
 213 Taking $\tilde{h}_1 = \max\{\beta_0 \aleph_3 + \mu, \beta_0 \aleph_1, \tau, |\beta'(\Gamma)| \aleph_1 \aleph_3\}$, we see that χ_1 satisfies Lips-
 214 chitz condition with respect to its arguments. By a similar argument, one can
 215 obtain Lipschitz constants \tilde{h}_i for $\chi_i, i = 2, \dots, 12$. Thus, there exists a positive
 216 constant Δ such that

$$\|\chi(t, X_1(t)) - \chi(t, X_2(t))\| \leq \Delta \|X_1(t) - X_2(t)\|. \quad (3.3)$$

217 Applying the integral operator (2.26) to both sides of model (2.13)–(2.24),
 218 we have

$$X(t) - X(0) = \frac{2(1-\theta)}{2-\theta} \chi(t, X(t)) + \frac{2\theta}{2-\theta} \int_0^t \chi(s, X(s)) ds. \quad (3.4)$$

219 Now, we define a recursive formula

$$X_n(t) = X(0) + \frac{2(1-\theta)}{2-\theta} \chi(t, X_{n-1}(t)) + \frac{2\theta}{2-\theta} \int_0^t \chi(s, X_{n-1}(s)) ds. \quad (3.5)$$

From (3.4) and (3.5), we obtain

$$\begin{aligned} \|X(t) - X_n(t)\| &\leq \frac{2(1-\theta)}{2-\theta} \|\chi(t, X(t)) - \chi(t, X_{n-1}(t))\| \\ &\quad + \frac{2\theta}{2-\theta} \int_0^t \|\chi(s, X(s)) - \chi(s, X_{n-1}(s))\| ds. \end{aligned} \quad (3.6)$$

220 Using (3.1), (3.6) becomes

$$\begin{aligned} \|X(t) - X_n(t)\| &\leq \frac{2(1-\theta)}{2-\theta} \Delta \|X(t) - X_{n-1}(t)\| \\ &\quad + \frac{2\theta}{2-\theta} \Delta \int_0^t \|X(s) - X_{n-1}(s)\| ds, \\ &\leq \left(\frac{2(1-\theta)}{2-\theta} + \frac{2\theta}{2-\theta} t_0 \right) \Delta \|X(t) - X_{n-1}(t)\|. \end{aligned}$$

221 By iteration on n

$$\|X(t) - X_n(t)\| \leq \left[\left(\frac{2(1-\theta)}{2-\theta} + \frac{2\theta}{2-\theta} t_0 \right) \Delta \right]^n \|X(t) - X_0(t)\|. \quad (3.7)$$

222 Existence of solution follows by taking the limit on both sides of (3.7).

223 Next, we establish the uniqueness of solution. Assume $X^1(t)$ and $X^2(t)$ are
 224 different solutions of model (2.13)–(2.24), then

$$\begin{aligned} \|X^1(t) - X^2(t)\| &\leq \frac{2(1-\theta)}{2-\theta} \|\chi(t, X^1(t)) - \chi(t, X^2(t))\| \\ &\quad + \frac{2\theta}{2-\theta} \int_0^t \|\chi(s, X^1(s)) - \chi(s, X^2(s))\| ds. \end{aligned}$$

225 Inequality (3.1) implies

$$\|X^1(t) - X^2(t)\| \leq \left(\frac{2(1-\theta)}{2-\theta} + \frac{2\theta}{2-\theta} t_0 \right) \Delta \|X^1(t) - X^2(t)\|.$$

226 Condition (3.2) implies

$$\|X^1(t) - X^2(t)\| \leq 0.$$

227 Uniqueness of solution follows immediately. \square

228 4. Disease-free equilibrium solution

229 Here, we find the equilibrium points, obtain the basic reproduction number
 230 and give some qualitative results. The disease-free equilibrium solution of model
 231 (2.13)–(2.24) is given as

$$\begin{aligned} \Upsilon &= (H_S^0, H_E^0, H_I^0, H_Q^0, H_R^0, V^0, E_S^0, E_L^0, E_I^0, K^0, B^0, T^0), \\ &= \left(\frac{\Lambda}{\mu}, 0, 0, 0, 0, 0, \frac{\lambda}{d}, 0, 0, \frac{\lambda_K}{\varpi_K}, 0, 0 \right). \end{aligned} \quad (4.1)$$

Below, we obtain the basic reproduction number by expressing the disease class of the model as the difference between the new infection vector \mathcal{F}_{new} and transmission vector $\mathcal{F}_{\text{trans}}$.

$$\begin{aligned} \begin{bmatrix} D_t^\theta H_E \\ D_t^\theta H_I \\ D_t^\theta H_Q \\ D_t^\theta V \\ D_t^\theta E_L \\ D_t^\theta E_I \end{bmatrix} &= \mathcal{F}_{\text{new}} - \mathcal{F}_{\text{trans}} \\ &= \begin{bmatrix} \beta(V) H_I H_S \\ 0 \\ 0 \\ \frac{\beta\eta(V) H_I (H_S - 1)}{H_E + H_I + 1} \\ \varepsilon E_S V \\ 0 \end{bmatrix} - \begin{bmatrix} (\sigma + \mu + \pi_E) H_E \\ -\sigma H_E + (\mu + \delta_I + \pi_I + \rho_I) H_I \\ -\pi_E H_E - \pi_I H_I + (\mu + \rho_Q + \delta_Q) H_Q \\ -a E_I + \kappa V B + m V \\ \gamma_1 K E_L + \gamma_2 T E_L + (\phi + d) E_L \\ -\phi E_L + \gamma_1 K E_I + \gamma_2 T E_I + d E_I \end{bmatrix}. \end{aligned}$$

232 We obtain the Jacobian matrices $\mathcal{J}_{\text{new}}^{\mathcal{F}}$, $\mathcal{J}_{\text{trans}}^{\mathcal{F}}$ of \mathcal{F}_{new} and $\mathcal{F}_{\text{trans}}$ at the
 233 disease-free equilibrium point. Then, we compute

$$\begin{aligned} \mathfrak{J} &= \mathcal{J}_{\text{new}}^{\mathcal{F}} (\mathcal{J}_{\text{trans}}^{\mathcal{F}})^{-1} \\ &= \begin{bmatrix} \frac{\beta(0)\Lambda\sigma}{\mu(\sigma + \mu + \pi_E)(\mu + \delta_I + \pi_I + \rho_I)} & \frac{\beta(0)\Lambda}{\mu(\sigma + \mu + \pi_E)} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ \frac{\eta\beta(0)(\Lambda - \mu)\sigma}{\mu(\sigma + \mu + \pi_E)(\mu + \delta_I + \pi_I + \rho_I)} & \frac{\eta\beta(0)(\Lambda - \mu)}{\mu(\sigma + \mu + \pi_E)} & 0 & 0 & 0 & 0 \\ 0 & 0 & \frac{\varepsilon\lambda}{dm} & \frac{\varepsilon\lambda a\phi}{dm\left(\frac{\lambda_K\gamma_1}{\varpi_K} + \phi + d\right)\left(\frac{\lambda_K\gamma_1}{\varpi_K} + d\right)} & \frac{\varepsilon\lambda a}{dm\left(\frac{\lambda_K\gamma_1}{\varpi_K} + d\right)} & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \end{bmatrix}. \end{aligned}$$

234 Finding the eigenvalues of the above matrix, we have

$$\text{Basic reproduction number, } \mathfrak{R}_0 = \max\{\mathfrak{R}_0^B, \mathfrak{R}_0^W\},$$

235 where

$$\begin{aligned} \mathfrak{R}_0^B &= \frac{\beta(0)\Lambda\sigma}{\mu(\sigma + \mu + \pi_E)(\mu + \delta_I + \pi_I + \rho_I)}, \\ \mathfrak{R}_0^W &= \frac{\varepsilon\lambda a\phi\varpi_K^2}{dm(\lambda_K\gamma_1 + \varpi_K\phi + \varpi_K d)(\lambda_K\gamma_1 + \varpi_K d)}. \end{aligned}$$

236 \mathfrak{R}_0^B is the basic reproduction number corresponding to the epidemiological
 237 (between host) part of the model while \mathfrak{R}_0^W corresponds to the immunological
 238 (within host) part.

239 Consider the following fractional-order linear system with Caputo-Fabrizio
 240 derivative:

$$D_t^\theta \mathcal{X}(t) = A\mathcal{X}(t), \quad (4.2)$$

241 where $\mathcal{X}(t) \in \mathbb{R}^n$, $A \in \mathbb{R}^{n \times n}$, and $0 < \theta < 1$. The following definition and result
 242 will be needed in the sequel:

243 **Definition 4.1.** ([64, Definition 2]) The characteristic equation of system (4.2)
 244 is

$$\det(s(I - (1 - \theta)A) - \theta A) = 0.$$

245 **Lemma 4.2.** ([64, Theorem 1]) If the matrix $(I - (1 - \theta)A)$ is invertible, then
 246 (4.2) is asymptotically stable if and only if the real parts of the roots of the
 247 characteristic equation of system (4.2) are negative.

248 We have the following result on stability of the disease-free equilibrium point:

249 **Theorem 4.3.** The disease-free equilibrium Υ of (2.13)–Eq.(2.24) is locally
 250 asymptotically stable if $\mathfrak{R}_0 < 1$.

251 *Proof.* Lemma 4.2 is used to establish this result. We obtain matrix A by
 252 linearizing the model (2.13)–(2.24) at the disease-free equilibrium point:

$$A = \begin{bmatrix} -\mu & 0 & -\frac{\beta(0)\Lambda}{\mu} & 0 & \tau & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -C_1 & \frac{\beta(0)\Lambda}{\mu} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \sigma & -C_2 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \pi_E & \pi_I & -C_3 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & \rho_I & \rho_Q & -(\mu + \tau) & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & \beta(0)\eta\left(\frac{\Lambda}{\mu} - 1\right) & 0 & 0 & -m & 0 & 0 & a & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\varepsilon\frac{\lambda}{d} & -d & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \varepsilon\frac{\lambda}{d} & 0 & -C_4 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & \phi & -C_5 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \lambda_K\xi & 0 & 0 & 0 & -\varpi_K & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \alpha_B & 0 & 0 & 0 & 0 & -\varpi_B & 0 \\ 0 & 0 & 0 & 0 & 0 & \alpha_T & 0 & 0 & 0 & 0 & 0 & -\varpi_T \end{bmatrix},$$

253 where

$$C_1 = \sigma + \mu + \pi_E, \quad C_2 = \mu + \delta_I + \pi_E + \rho_I, \quad C_3 = \mu + \rho_Q + \delta_Q,$$

254

$$C_4 = \frac{\lambda_K\gamma_1}{\varpi_K} + \phi + d, \quad C_5 = \frac{\lambda_K\gamma_1}{\varpi_K} + d.$$

Next, we show that $(I - (1 - \theta)A)$ is invertible and the roots of $\det(s(I - (1 - \theta)A) - \theta A) = 0$ have negative real parts. After a few lines of calculation, we have

$$\begin{aligned} |I - (1 - \theta)A| &= \left(1 + (1 - \theta)(C_1 + C_2) + (1 - \theta)^2 \left(C_1C_2 - \frac{\Lambda\beta(0)\sigma}{\mu}\right)\right) (\mu(1 - \theta) + 1) \\ &\quad \times ((1 - \theta)C_3 + 1)(\mu(1 - \theta) + \tau(1 - \theta) + 1)((1 - \theta)C_5 + 1)(m(1 - \theta) + 1) \\ &\quad \times (d(1 - \theta) + 1)((1 - \theta)C_4 + 1)((1 - \theta)\varpi_K + 1)((1 - \theta)\varpi_B + 1)((1 - \theta)\varpi_T + 1) \neq 0, \end{aligned}$$

255 for $0 < \theta < 1$. This shows that $(I - (1 - \theta)A)$ is invertible. Now, the roots of
 256 $\det(s(I - (1 - \theta)A) - \theta A) = 0$ are

$$s_1 = -\frac{\theta\varpi_T}{1 + \varpi_T(1 - \theta)}, \quad s_2 = -\frac{\theta\varpi_B}{1 + \varpi_B(1 - \theta)}, \quad s_3 = -\frac{\theta\varpi_K}{1 + \varpi_K(1 - \theta)}, \quad s_4 = -\frac{\theta d}{1 + d(1 - \theta)},$$

257

$$s_5 = -\frac{\theta\mu}{1 + \mu(1 - \theta)}, \quad s_6 = -\frac{\theta(\mu + \tau)}{1 + (\mu + \tau)(1 - \theta)}, \quad s_7 = -\frac{\theta C_3}{1 + C_3(1 - \theta)},$$

258

$$s_8 = -\frac{2C_1C_2(1 - \theta)(1 - \mathfrak{R}_0^B) + (C_1 + C_2) + \sqrt{(C_1 + C_2)^2 - 4C_1C_2(1 - \mathfrak{R}_0^B)}}{2[C_1C_2(1 - \theta)^2(1 - \mathfrak{R}_0^B) + (C_1 + C_2)(1 - \theta) + 1]},$$

259

$$s_9 = -\frac{2C_1C_2(1 - \theta)(1 - \mathfrak{R}_0^B) + (C_1 + C_2) - \sqrt{(C_1 + C_2)^2 - 4C_1C_2(1 - \mathfrak{R}_0^B)}}{2[C_1C_2(1 - \theta)^2(1 - \mathfrak{R}_0^B) + (C_1 + C_2)(1 - \theta) + 1]}.$$

260 The remaining roots can be obtained from the equation

$$s^3 + \mathfrak{P}_2s^2 + \mathfrak{P}_1s + \mathfrak{P}_0 = 0, \quad (4.3)$$

261 where

$$\begin{aligned}\mathfrak{P}_2 &= \frac{[mC_4C_5(1-\theta)^2(1-\mathfrak{R}_0^W) + 2(m(C_4+C_5) + C_4C_5)(1-\theta) + (m+C_4+C_5)]\theta}{mC_4C_5(1-\theta)^3(1-\mathfrak{R}_0^W) + (m(C_4+C_5) + C_4C_5)(1-\theta)^2 + (C_4+C_5+m)(1-\theta) + 1}, \\ \mathfrak{P}_1 &= \frac{[3mC_4C_5(1-\theta)(1-\mathfrak{R}_0^W) + m(C_4+C_5) + C_4C_5]\theta^2}{mC_4C_5(1-\theta)^3(1-\mathfrak{R}_0^W) + (m(C_4+C_5) + C_4C_5)(1-\theta)^2 + (C_4+C_5+m)(1-\theta) + 1}, \\ \mathfrak{P}_0 &= \frac{mC_4C_5(1-\mathfrak{R}_0^W)\theta^3}{mC_4C_5(1-\theta)^3(1-\mathfrak{R}_0^W) + (m(C_4+C_5) + C_4C_5)(1-\theta)^2 + (C_4+C_5+m)(1-\theta) + 1}.\end{aligned}$$

262 Obviously, $s_1 - s_7$ are negative real numbers, s_8, s_9 have negative real parts
263 provided $\mathfrak{R}_0^B < 1$. For $s_{10} - s_{12}$, Routh-Hurwitz criterion is used to show that
264 (4.3) has roots with negative real parts. By Routh-Hurwitz criterion, (4.3) has
265 roots with negative real parts if and only if $\mathfrak{P}_2, \mathfrak{P}_1$ and \mathfrak{P}_0 are positive and
266 $\mathfrak{P}_2\mathfrak{P}_1 > \mathfrak{P}_0$ [65]. Obviously, $\mathfrak{P}_2 > 0, \mathfrak{P}_1 > 0$ and $\mathfrak{P}_0 > 0$ provided $\mathfrak{R}_0^W < 1$.
267 After a few lines of calculations, we have

$$\begin{aligned}\mathfrak{P}_2\mathfrak{P}_1 - \mathfrak{P}_0 &= 2(1-\theta) [mC_4C_5(1-\mathfrak{R}_0^W)(1-\theta) + m(C_4+C_5) + C_4C_5]^2 \\ &\quad + mC_4C_5(1-\mathfrak{R}_0^W)(m(C_4+C_5) + C_4C_5)(1-\theta)(3-\theta) \\ &\quad + (C_4+C_5)(m(m+C_4+C_5) + C_4C_5) + mC_4C_5\mathfrak{R}_0^W > 0.\end{aligned}$$

268 The result follows from Lemma 4.2. \square

269 5. Simulations and discussions

270 This section is devoted to simulations of various forms as well as discussions
271 of results. Codes are written in MATLAB[®] for this purpose. For the choice of
272 $\beta(V)$, it is assumed that $\beta(V)$ has a base transmission rate and increases as the
273 viral load increases.

$$\beta(V) = \beta_1 \left(1 + \frac{\psi V}{\varphi + V} \right).$$

274 Where φ is the half saturation constant for viral shedding and ψ is the influence
275 of viral load on transmission.

276 5.1. Parameter estimation

277 We use the COVID-19 data provided by Malaysian government from 10/01/2022
278 through 10/03/2022 which is publicly available at [54] for our model fitting. We
279 choose this range because of the high spread of the virus in Malaysia at this
280 period.

281 For this purpose, we add two new compartments - confirmed cases (H_C) and
282 confirmed death cases (H_D) to model (2.13)–(2.12).

$$D_t^\theta H_D = \delta_Q H_Q + \delta_I H_I, \quad (5.1)$$

$$D_t^\theta H_C = \pi_E H_E + \pi_I H_I. \quad (5.2)$$




Figure 5.1: Real-life COVID-19 data and lines of best

284 The quarantined compartment (Q), death compartment and confirmed cases
 285 compartment are fitted to the "active cases", "cumulative death cases" and "cu-
 286 mulative confirmed cases" data respectively. As Malaysia is roughly a 33,000,000
 287 population country, we therefore set $S(0) = 33,000,000 - E(0) - I(0) - Q(0) - R(0)$.
 288 $Q(0)$ and $R(0)$ are taken from the data while $E(0)$ and $I(0)$ are estimated.

289 For the immunological part of the model, we fit our model to the mean viral
 290 load data of Hong Kong patients [66]. The model fitting for epidemiological and
 291 immunological parts are done simultaneously. Our simulation was carried out
 292 using "fmincon" package by MATLAB® [67]. The data available in [54, 66] is not
 293 sufficient to estimate all the parameters involved in the dynamics of the disease.
 294 We therefore rely on the values found in literature for some parameters and
 295 assumed values for some. Our estimated parameter values and other parameter
 296 values are contained in Table 2. From our model fitting, it was estimated that
 297 $E(0) = 1659$ and $I(0) = 982$ while the order of differentiation was estimated
 298 as 0.569 (ie $\theta = 0.569$). This therefore means that fractional order differential
 299 equations best fit the data than differential equations with classical differentiation.
 300 In other words, this study shows that including memory effects in modeling
 301 COVID-19 dynamics significantly improves the accuracy of the fit to the data.
 302 For subsequent simulations, we take $\theta = 0.569$. Figure 5.1 shows the fitted curves
 303 and the real-life data. Using the estimated parameter values, $\mathfrak{R}_0^B = 0.807$ while
 304 $\mathfrak{R}_0^W = 3.674$. This shows that the major driver of the dynamics of the disease
 305 (during the period used for parameter estimation) is the dynamics of the virus
 306 within host.

307 *5.2. Sensitivity analysis*

308 Sensitivity analysis helps to measure the influence of each parameter in the
 309 dynamics of infection being studied [68]. We investigate the influence of each
 310 parameter on the dynamics of the disease both locally and globally. While
 311 local sensitivity analysis examines the sensitivity of a variable or parameter with
 312 respect to change in a single parameter value, global sensitivity analysis examines
 313 the sensitivity of a variable or parameter with respect to change within the
 314 entire parameter range [69]. Global sensitivity analysis (GSA) seems to provide
 315 comprehensive result however, different methods of GSA can give different results
 316 and furthermore, the result of analysis greatly depends on the assumed probability
 317 distribution of the input parameters [68, 70]. Local sensitivity analysis, on the
 318 other hand, considers only the variation in one input parameter at a time, the
 319 sensitivity coefficient obtained can be used for comparison with other parameters
 320 independent of the range of parameter variations [70]. Considering the advantage
 321 of one approach over the other, both approaches are therefore used in this work.

322 *5.2.1. Local sensitivity analysis*


323 In order to determine the most essential parameters in the transmission
 324 dynamics of COVID 19, we perform a sensitivity analysis of the formulated
 325 model (2.13)–(2.24) according to [71].

326 **Definition 5.1.** The normalized forward sensitivity index, of a variable, v to a
 327 parameter p denoted by Υ_p^v , is denoted as a ratio of the relative change in the
 328 variable to the relative change in the parameter

$$\Upsilon_p^v = \frac{\partial v}{\partial p} \times \frac{p}{v}.$$

329 The magnitudes and signs of the sensitivity indices of the basic reproduction
 330 numbers \mathfrak{R}_0 with respect to model parameters obtained and shown in Figure 5.2
 331 reveal how changes in the model parameters affect the basic reproduction number.
 332 The parameters with positive indices suggest that an increase (or decrease) in
 333 the value of each of these parameters will lead to the increase (or decrease) in \mathfrak{R}_0 .
 334 For example, $\Upsilon_\beta^{\mathfrak{R}_0} = 1$, implies that increasing (or decreasing) the transmission
 335 rate, β , by 10% also increases (or decreases) the basic reproduction number,
 336 \mathfrak{R}_0 , by 10%, provided other parameters are constant. On the other hand, the
 337 parameters with negative indices suggest that an increase (or decrease) in the
 338 value of each of these parameters will lead to the decrease (or increase) in \mathfrak{R}_0 .

339 From the sensitivity indices in Figure 5.2, it can be seen that the basic
 340 reproduction number is more sensitive to the parameters corresponding to the in-
 341 host dynamics. Figure 5.2 suggests that immune response plays sensitive role in
 342 controlling the spread of the disease. It is worth mentioning that natural human
 343 death rate (μ), natural death rate of epithelial cell (d), human recruitment rate
 344 (Λ), epithelial cell recruitment rate (λ) have significant influence on \mathfrak{R}_0 , however
 345 control measures can not be built around these parameters. For example, the
 346 sensitivity indices in Figure 5.2 suggests that natural human death rate should

Figure 5.2: Sensitivity indices of \mathfrak{R}_0 to model parameters

347 be increased in other to curtail the spread of the virus. This is not good and
 348 therefore not implementable.

349 Other important parameters worthy of attention are the transmission rate
 350 (β), progression of exposed individuals to infectious compartment (σ), quarantine
 351 of both exposed and infectious individuals (π_E, π_I), rate at which susceptible
 352 epithelial cells are infected by SARS-CoV-2 (ϵ), progression of latently infected
 353 epithelia cells to infectious epithelial cells (ϕ), production rate of SARS-CoV-2
 354 by infected epithelial cells (a), viral clearance rate from biological environment
 355 (m). The basic reproduction number is positively sensitive to parameters $\beta, \sigma, \epsilon,$
 356 ϕ and a but negatively sensitive to π_E, π_I and m . Therefore the control measure
 357 be such that the values of the parameters with positive indices are reduced while
 358 the values of the parameters with negative indices are increased. Our point
 359 here is this, the sensitivity indices suggests that in order to curtail the spread
 360 of the virus, the following are necessary - use of drugs/medication to boost
 361 immune response, observance of COVID-19 protocol to reduce transmission,
 362 use of medication that prevents epithelial cells from being infected or prevents
 363 (or reduce) infected epithelial cell from producing the virus, use of drugs to
 364 hasten the clearance of virus from human body and contact tracing followed by
 365 quarantined of infected individuals.

366 5.2.2. Global sensitivity analysis

367 In order to further quantify the impact of each parameter on the basic repro-
 368 duction number (\mathfrak{R}_0), we adopt a sampling-based method called Latin hypercube
 369 sampling with partial rank correlation coefficient index, (LHS-PRCC). The goal

370 of LHS-PRCC is to identify key parameters whose uncertainties contribute to
 371 the inaccuracy of prediction and to rank these parameters by their level of
 372 influence in contributing to the prediction imprecision. The magnitude and the
 373 statistical significance (p -value) of the PRCC value of a parameter indicate the
 374 contribution of the uncertainty in the parameter to the model's prediction. The
 375 closer the PRCC value to +1 or -1 , the more strongly the parameter influences
 376 the outcome measure. The p -value is the probability of getting a correlation as
 377 large as the observed value by random chance, when the true correlation is zero.
 378 The PRCC value is significant if the p -value is small, say less than 0.05. For a
 379 comprehensive description of this method, we refer to [72, 73].

380 As a measure of uncertainty in our parameter values, we take 50% to the
 381 right and left of the parameter values given in Table 2 while \mathfrak{R}_0 is the input
 382 function. LHS/PRCC method with 5000 uniformly distributed samples from
 383 each parameter range were generated and used as simulation inputs. The PRCC
 384 for the model parameters are shown in Figures 5.3–5.5. The magnitude of
 385 PRCC shows the influence of the parameter on the dynamics of the disease, the
 386 PRCC sign (positive or negative) shows the qualitative relationship between the
 387 input parameter and the basic reproduction number while the p -value gives the
 388 significance of the PRCC value.

389 Firstly, we investigate the influence of uncertainties in each parameter on
 390 the epidemiological part of the model. This we do by taking \mathfrak{R}_0^B as the input
 391 function and obtain the PRCC result shown in Figure 5.3. Figure 5.3 shows
 392 the reproduction number \mathfrak{R}_0^B is strongly positively sensitive to human-human
 393 transmission rate (β), human recruitment rate (Λ) and progression rate from
 394 exposed compartment to infectious class (σ). However, the reproduction number
 395 \mathfrak{R}_0^B is strongly negatively sensitive to quarantine rate of exposed human (π_E),
 396 quarantine rate of infectious human (π_I), and natural human death rate (μ).
 397 These parameters (β , Λ , σ , π_E , π_I and μ) have high PRCC values which
 398 are statistically significant thus, uncertainty in any of these parameters is an
 399 important contributor to uncertainty in prevalence of the disease. While human-
 400 human transmission rate (β) and progression rate from exposed compartment
 401 to infectious class (σ) should be decreased, quarantine rate of exposed human
 402 (π_E) and quarantine rate of infectious human (π_I) should be increased in order
 403 to curtail the transmission of the virus. The scatter plots corresponding to
 404 parameters β , σ , π_E , and π_I indicate that with these parameters in their
 405 respective ranges, chances are that $\mathfrak{R}_0^B < 1$, a condition for disease control. Also
 406 since the PRCC values obtained for these parameters are statistically significant,
 407 understanding how to control these parameters will greatly help in controlling
 408 the spread of the virus among human. The PRCC value obtain for δ_I and ρ_I
 409 are very low which implies that these parameters have ignorable impact on the
 410 dynamics of the disease.

411 Secondly, we investigate the influence of uncertainties in each parameter on
 412 the in-host part of the model. This is done by taking \mathfrak{R}_0^W as the input function
 413 and obtain the PRCC result shown in Figure 5.4. One can see from Figure
 414 5.4 that all the parameters involved in the dynamics of the within host part
 415 have significant PRCC values. Rate at which E_S are infected by SARS-CoV-2




Figure 5.3: PRCC showing the influence of each parameter on R_0^B




Figure 5.4: PRCC showing the influence of each parameter on \mathfrak{R}_0^W

416 (ϵ), recruitment rate of susceptible epithelial cell (λ), rate at which latently
 417 infected epithelial cells become infectious (ϕ), death rate for natural killer cells
 418 (ϖ_K) and production rate of SARS-CoV-2 (a) all have positive correlation
 419 with reproduction number \mathfrak{R}_0^W . These parameters need to be reduced in order
 420 to control the dynamics of the virus within a host individual however, looking
 421 through the scatter plots corresponding to these parameters, ϖ_K has the greatest
 422 PRCC value and with this parameter in its range, chances are that $\mathfrak{R}_0^W < 1$. The
 423 implication of this is that having vaccines that boost human immunity system
 424 is paramount to curtaining SARS-CoV-2 dynamics. \mathfrak{R}_0^W is negatively sensitive
 425 to natural death rate of epithelial cells (d), natural viral clearance rate from
 426 biological environment (m), constant regeneration rate of natural killer cells
 427 (λ_K) and killing rate of infected epithelial cells by natural killer cell (γ_1). Again,
 428 one can see that parameters corresponding to immunity are the parameters with
 429 most correlation coefficient.

430 Lastly, we have Figure 5.5 which shows the impact of the within-host and
 431 between-host parameters on the basic reproduction number. It is obvious from
 432 the PRCC values in Figure 5.5 that the influence of between-host parameters is
 433 almost insignificant compared to the influence of the within-host parameters. This
 434 suggests that in order to control the dynamics of the virus, great attention must be

435 paid to the behaviour of the virus within infected individuals while not neglecting
 436 the transmission dynamics. It is also very clear from the scatter diagrams that
 437 no single parameter can single-handedly make the basic reproduction number
 438 less than unity. This suggests that multiple intervention strategies must be
 439 implemented if the spread of SARS-CoV-2 will be curtailed.

440 5.3. Model simulations

441 In this section, model (2.13)–(2.12) is solved numerically using two-step
 442 fractional Adams Bashforth method (see [74, Theorem 3.2]). Codes are written
 443 in MATLAB® for this purpose. Effects of control strategies on the dynamics
 444 of the disease are investigated numerically. The parameter values in Table 2
 445 are used to carry out the numerical simulations. We take $H_S(0) = 32,794,000$,
 446 $H_E(0) = 3,000$, $H_I(0) = 1,000$, $H_Q(0) = 2,000$, $H_R(0) = 200,000$, $V(0) = 10^4$,
 447 $E_S(0) = 200,000$, $E_L(0) = 700$, $E_I(0) = 300$, $K(0) = 38,835$, $B(0) = 10$ and
 448 $K(0) = 10$.

449 Solving model (2.13)–(2.24) numerically, we obtain the graphs in Figure
 450 5.6. It can be seen that the population of infected epithelial cells decreases.
 451 This is as a result of infection by SARS-CoV-2 and the killing effects of natural
 452 killer cells and cytotoxic T-cells. This observation is supported by the work of
 453 Deinhardt-Emmer et al [75]. The viral load also decreases due to the presence
 454 of B-lymphocytes and the decrease in the population of epithelial cells. In spite
 455 of these immune responses, the disease still persists in human population. This
 456 is because the remaining virus in human body is enough to ensure that the
 457 disease persists in human population. While most articles on the epidemiological
 458 dynamics of COVID-19 concluded that reducing the transmission such that
 459 $\mathfrak{R}_0^B < 1$ will help in curtailing the spread of the virus, this research has shown
 460 that this condition is not enough. Both $\mathfrak{R}_0^B < 1$ and $\mathfrak{R}_0^W < 1$ are necessary
 461 before the disease can be curtailed.

462 5.3.1. Influence of viral load on transmission

463 The condition $\mathfrak{R}_0 < 1$ guarantees the local stability of the disease-free
 464 equilibrium, however it is shown in Figure 5.7 that the disease still persists in
 465 human population when $\mathfrak{R}_0 < 1$. This is because the transmission rate depends
 466 on the average viral load in infectious individuals whereas the basic reproduction
 467 number does not capture this. We therefore have the effective basic reproduction
 468 number

$$\text{Effective basic reproduction number, } \text{eff}\mathfrak{R}_0 = \max \left\{ \text{eff}\mathfrak{R}_0^B, \mathfrak{R}_0^W \right\},$$

469 where

$$\begin{aligned} \text{eff}\mathfrak{R}_0^B &= \frac{\beta_1(1+\psi)\Lambda\sigma}{\mu(\sigma + \mu + \pi_E)(\mu + \delta_I + \pi_I + \rho_I)}, \\ \mathfrak{R}_0^W &= \frac{\varepsilon\lambda a\phi\varpi_K^2}{dm(\lambda_K\gamma_1 + \varpi_K\phi + \varpi_K d)(\lambda_K\gamma_1 + \varpi_K d)}. \end{aligned}$$




Figure 5.5: PRCC showing the influence of each parameter on \mathfrak{R}_0




Figure 5.6: Simulation of (2.13)–(2.24) using parameter values in Table 2




Figure 5.7: Influence of viral load on transmission

470 where ψ is the parameter that accounts for the increase in transmission rate
 471 caused by viral load. It can be seen in Figure 5.7 that ψ has a significant impact
 472 on the dynamics and control of SARS-CoV-2. The implication of this is that
 473 incomplete recovery from COVID-19 is a treat to the control of the disease. The
 474 assumption that transmission rate depends on the viral load was also made in
 475 [34] however, there was no discussion on its influence on transmission dynamics
 476 of the disease. We conclude this session by stating that $\mathfrak{R}_0 \leq^{\text{eff}} \mathfrak{R}_0 < 1$ is the
 477 requirement for the disease control.

478 5.3.2. Intervention strategies

479 Next we explore various intervention strategies. For each intervention strategy,
 480 we compute the percentage death averted (PDA). PDA is the ratio of the total
 481 number of death averted to the total number of death when there is no control
 482 measure while the total number of death averted (TDA) is the difference between
 483 the total death due to infection over the simulation period in the absences of
 484 control and the total death due to infection when there is control.

$$\text{PDA} = \frac{\int_0^T [\delta_I H_I + \delta_Q H_Q]_{\text{without control}} dt - \int_0^T [\delta_I H_I + \delta_Q H_Q]_{\text{with control}} dt}{\int_0^T [\delta_I H_I + \delta_Q H_Q]_{\text{without control}} dt}$$

485

486 Vaccine

487 There are many COVID-19 vaccines being used in countries of the world
 488 - Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Gamaleya Sputnik V,
 489 Janssen Ad26.COV2.S, Oxford/AstraZeneca AZD1222 and Covishield (Ox-
 490 ford/AstraZeneca formulation) [76]. COVID-19 vaccines help the body to develop
 491 immunity to SARS-CoV-2. It normally takes some weeks after vaccination for
 492 the body to build resistance against the virus. It is therefore possible for a
 493 person to still contract COVID-19 just after vaccination. This is due to the fact
 494 that the vaccine has not had sufficient time to offer protection [77]. It was also
 495 noted in [78] that COVID-19 vaccine does not provide 100% protection. Since
 496 the vaccine works with immune system, we numerically study the impact of

497 natural K-cells, B-lymphocytes and cytotoxic T-cells on the dynamics of the
498 disease in what follows.

499 Firstly, we consider vaccination leading to increased amount of natural K-
500 cells, B-lymphocytes and cytotoxic T-cells. As shown in Figure 5.8, increase in
501 the population of immune compartments lead to a decline in the peak values of
502 viral load and infected epithelial cells. However, in the human population, the
503 impact of this intervention strategy is not seen until after a later time (of about
504 35 days). The PDA of the strategy is in Table 3.

505 Secondly, we consider vaccination leading to increased efficacy of natural K-
506 cells, B-lymphocytes and cytotoxic T-cells. This is shown in Figure 5.9. Increase
507 in the efficacy of immune compartments lead to a rapid decline in the peak
508 values of viral load and infected epithelial cells. Also in the case, it will take
509 a while before the impact of this strategy is found in human population. This
510 strategy appears (pictorially) to be more effective however Table 3 shows that it
511 averts less human death when the vaccine improves the efficacy of the immune
512 components by 10% and 30%.

513

514

515 **Social distancing, face mask and other measures to reduce transmission** 516 **rate**

517 It is known that the countries of the world have initiated certain control measures
518 (such as frequent hand washing with alcohol-based sanitizer, use of face masks in
519 public, social distancing, movement restrictions, etc). Malaysian government has
520 also initiated such containment measures during the period used for parameter
521 estimation. This is responsible for the low value of β and high values of π_E and
522 π_I . Yet in this section, we consider the cases where the transmission rate (β)
523 is further lowered. Figure 5.10 shows the impact of this strategy. It is obvious
524 that the infected human compartments reduce drastically which accounts for
525 the high percentage death averted (see Table 3). Figure 5.10 further shows that
526 reduction in transmission rate has negligible impact on within-host dynamics.

527 When there is 30% decrease in transmission rate, ${}^{\text{eff}}\mathfrak{R}_0^\beta = 0.902$, $\mathfrak{R}_0^W = 3.674$.
528 This accounts for the drastic reduction in the populations of infected individuals.
529 The average viral load per infectious individual (V) also decreases however, the
530 virus remains in the system. A quick way to know that the virus remains in the
531 body is to check the volume of immune cells. A high volume of immune cells
532 is an indication of the presence of virus/pathogens. The remnant virus in the
533 body can cause another surge any time the COVID-19 protocol is relaxed. Thus,
534 taken care of epidemiological components only provides a temporary measure to
535 curtailing the spread of the virus, the within-host dynamics will drive the entire
536 dynamics and the virus will continue to live within human population.

537 Figure 5.11 shows the effect of increase in the rate at which infected individuals
538 are detected and quarantined. It is reasonable to assume that it takes a minimum
539 of 1 day to detect and quarantine an infected individual. In Figure 5.11, the
540 infected human compartments reduce drastically which accounts for the high
541 percentage death averted (see Table 3). Also Figure 5.11 shows that increase in




Figure 5.8: Simulation of (2.13)–(2.24) considering the increase in proliferation rates of immune cells




Figure 5.9: Simulation of (2.13)–(2.24) with increase in the strength of immune cells




Figure 5.10: Simulation of (2.13)–(2.24) with reduction in transmission rate

542 quarantine rate has negligible impact on within-host dynamics.

543

544 **Reduction in viral infection of epithelial cells using medication or** 545 **vaccine**

546 Although there is no particular medication for treating COVID-19, people can
 547 recover by following a treatment protocol. Nonetheless, there are few questions
 548 to consider: Can we have drugs or vaccines that can prevent the epithelial cells
 549 from being infected? Can we have drugs or vaccines that can prevent the infected
 550 epithelial cells from reproducing the virus? Interferon, a component of human
 551 immune system interfere with viral replication and protects uninfected cells from
 552 the virus. Interferons, are produced and secreted by infected cells following virus
 553 infection. The secreted interferons act on neighboring cells to induce enzymes
 554 that render these cells more resistant to viral infection [43]. Resistance to viral




Figure 5.11: Simulation of (2.13)–(2.24) with increase in the rate at which infected individuals are detected and quarantined

555 infection causes reduction in the infection of epithelial cells by SARS-CoV-2. We
 556 therefore investigate the effect of the reduction of infection of epithelial cells by
 557 the virus as well as the reduction in the production rate of SARS-CoV-2.

558 Figure 5.12 shows the effects of the reduction of infection of epithelial cells by
 559 the virus as well as the reduction in the production rate of SARS-CoV-2. This
 560 strategy lowers the peak values of viral load and infected epithelial cells however
 561 it has no significant effect on the immune cells. Figure 5.12 and Table 3 show
 562 that this strategy does not have immediate impact on the population of infected
 563 human until when it is 50% effective. This intervention strategy is very good
 564 when combined with other strategies. Table 3 shows a drastic increase in PDA
 565 when this strategy is combined with other strategies. This further suggests that
 566 vaccines that offer at least 50% reduction in ε , a and at least 50% increase in κ ,
 567 γ_1 , γ_2 , λ_K , α_B , α_T will have a notable impact in controlling the spread of the
 568 virus. Our point here is that vaccine/medication should be made to achieve the
 569 following purpose: boost immune response, prevents epithelial cells from being
 570 infected or prevents (or reduce) infected epithelial cell from producing the virus,
 571 hasten the clearance of virus from human body.

572 5.3.3. Influence of memory on the disease dynamics

573 Memory indicates the dependence of a system not only on the present state
 574 of the system, but also on the previous history of the system. One advantage
 575 of using fractional order differential equations is that it incorporates memory.
 576 In Figure 5.13, we present the effect of memory on the dynamics of the disease
 577 on human population. Parameter values in Table 2 are used for our simulation.
 578 The dynamics of the disease changes more rapidly as the order of the derivative
 579 tends to one ($\theta \rightarrow 1$) while the infection reaches greater peak value as the
 580 order of the derivative tends to zero ($\theta \rightarrow 0$). This is due to the contribution
 581 by the previous history of the system. Caputo-Fabrizio fractional derivative
 582 has a fading memory [37]. Although fractional derivative incorporates memory,
 583 Caputo-Fabrizio fractional derivative is such that the dynamics of the disease is
 584 more influenced by the weight given to the moments near the present, and the
 585 further we go back in time, the more the weight decreases.

586 6. Conclusion

587 In this study, we propose a deterministic model which links between-host
 588 (population transmission) dynamics with within-host (disease processes within
 589 a single host) dynamics. Immune response is incorporated into our model in
 590 order to understand the interaction between SARS-CoV-2 and immune cells
 591 and how this inform the transmission from human to human. Considering the
 592 fact that disease dynamics leaves a memory in human immunologically and
 593 epidemiologically, a compartmentalized model with fractional derivative in the
 594 sense of Caputo-Fabrizio is proposed. The existence and uniqueness of solution
 595 to the model is established by fixed point method. The disease-free equilibrium
 596 solution is found to be locally asymptotically stable when $\mathfrak{R}_0 < 1$. Parameters




Figure 5.12: Simulation of (2.13)–(2.24) with decrease in viral infection of epithelial cells

Table 3: PDA of intervention strategies

Intervention strategy		PDA	
Vaccination	Increased proliferation rate of immune cells (V_1)	10% increase in $\lambda_K, \alpha_B, \alpha_T$	1.08%
		30% increase in $\lambda_K, \alpha_B, \alpha_T$	3.33%
		50% increase in $\lambda_K, \alpha_B, \alpha_T$	5.68%
		70% increase in $\lambda_K, \alpha_B, \alpha_T$	8.07%
	Increased efficacy of immune cells (V_2)	10% increase in $\kappa, \gamma_1, \gamma_2$	0.10%
		30% increase in $\kappa, \gamma_1, \gamma_2$	1.33%
		50% increase in $\kappa, \gamma_1, \gamma_2$	4.51%
		70% increase in $\kappa, \gamma_1, \gamma_2$	9.18%
	$(V_1) \& (V_2)$	10% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	1.40%
		30% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	7.21%
		50% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	16.50%
		70% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	23.48%
Social distancing, face mask and other measures to reduce transmission	Reduction in transmission rate	10% decrease in β	65.86%
		20% decrease in β	86.52%
		30% decrease in β	93.45%
	Increase in quarantine rate	$\pi_E = 0.9, \pi_I = 0.9$	73.36%
		$\pi_E = 1.0, \pi_I = 0.9$	86.85%
		$\pi_E = 1.0, \pi_I = 1.0$	93.11%
Reduction in viral infection of epithelial cells using medication or vaccine	Reduction in viral infection of epithelial cells (V_3)	10% reduction in ε and a	0%
		30% reduction in ε and a	0%
		50% reduction in ε and a	5.32%
		70% reduction in ε and a	19.31%
	$(V_1), (V_2), (V_3)$	50% reduction in ε, a and 50% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	22.82%
		70% reduction in ε, a and 70% increase in $\kappa, \gamma_1, \gamma_2, \lambda_K, \alpha_B, \alpha_T$	37.05%




Figure 5.13: Simulation of (2.13)–(2.24) showing the effect of memory on the disease dynamics

597 are estimated by fitting the model to four sets of real-life data simultaneously.
 598 We use cumulative confirmed cases, cumulative death cases and active cases data
 599 provided by Malaysian government which is publicly available at [54] for our
 600 model fitting. For the immunological part of the model, we fit our model to the
 601 mean viral load data of Hong Kong patients [66]. Local and global sensitivity
 602 analysis are carried via normalize forward sensitivity index and Latin hypercube
 603 sampling with partial rank correlation coefficient index respectively. Lastly the
 604 model is solved numerically using two-step fractional Adams-Bashforth method
 605 and various intervention strategies are investigated. Percentage death averted is
 606 computed to compare various intervention strategies.

607 By data fitting, parameters are estimated and we see that within-host dy-
 608 namics is the major driver of SARS-CoV-2 dynamics during the period used
 609 for data fitting. Data fitting further shows that the order of differential equa-
 610 tions involved in the model is 0.569. This therefore means that fractional order
 611 differential equations best fit the data than differential equations with classical
 612 differentiation.

613 Sensitivity analysis helps to measure the influence of each parameter in the
 614 dynamics of infection being studied. While local sensitivity analysis (LSA)
 615 measures the influence of a parameter on the disease dynamics when other
 616 parameters are constant, global sensitivity analysis (GSA) measures the influence
 617 of uncertainties in parameter values on disease dynamics. Both are needed in
 618 order to know the parameters that influence the dynamics of the disease and to
 619 propose control measures. LSA reveals that immune response plays sensitive role
 620 in controlling the spread of the disease. It further shows that viral transmission
 621 rate, progression of exposed individuals to infectious compartment, rate at which
 622 susceptible epithelial cells are infected by SARS-CoV-2, production rate of SARS-
 623 CoV-2 by infected epithelial cells are to be controlled in order to curtail the
 624 spread of the disease. GSA reveals that no single parameter can single-handedly
 625 make the basic reproduction number less than unity. Thus, suggesting that
 626 multiple intervention strategies must be implemented if the spread of SARS-
 627 CoV-2 will be curtailed. Both GSA and LSA suggest that in order to curtail
 628 the spread of the virus, the following are necessary: use of drugs/medication
 629 to boost immune system, use of medication that prevents epithelial cells from
 630 being infected or prevents (or reduce) infected epithelial cell from producing the
 631 virus and observance of COVID-19 protocol to reduce transmission.

632 It is shown, by simulations that in order to reduce human death, it is
 633 encouraged to strictly maintain measures that reduce transmission of the virus,
 634 however to automatically solve the problem of SARS-CoV-2, attention must be
 635 paid to the use of vaccines/medications which greatly improve on human immune
 636 systems, prevent epithelial cells from being infected and also prevent infected
 637 epithelial cells from reproducing more virus. While immune system (innate and
 638 adaptive) needs to be boosted greatly, it is crucial that adaptive immune cells
 639 be made to specifically recognise SARS-CoV-2. This is because occasionally, the
 640 adaptive immune system may fail to distinguish between what is foreign and
 641 what is not and reacts destructively against the host's own molecules [42].

642 For our simulation, we employed a particular type of β that varies as an

643 increasing function of V . This selection was made based on the fact that SARS-
 644 CoV-2 transmission rises with an increase in viral load [44]. Despite using a
 645 specific form of β for the simulation, the outcome of our study remains applicable
 646 to any β that is an increasing function of V . Generalization of the findings to
 647 the case where β is a piecewise continuous function or time-dependent function
 648 is straightforward with little modifications. Summarily, the assumption that
 649 the transmission rate increases with viral load aligns with clinical findings and
 650 underscores the importance of our model in emphasizing the effects of pandemic
 651 prevention and control measures.

652 Our proposed model is based on other assumptions, one of which is that the
 653 entire population is homogeneously mixed. Heterogeneity may be incorporated
 654 using a risk-structured model. Another limitation of our multiscale model is
 655 that it assumes individual hosts have the same internal states at a time. An
 656 improvement in this direction is subject to further study but possible in view
 657 of [35, 79]. Nonetheless the result of this work is robust as it presents the
 658 efforts of public health interventions to control SARS-CoV-2 which are focused
 659 on the reduction of human-to-human transmission of the virus on one hand
 660 and medical interventions to treat the disease which are focused on enhancing
 661 immune response on the other hand.

662

663 Acknowledgments

664 Authors like to thank the School of Mathematical Sciences, University Sains
 665 Malaysia for providing the facilities used for the research. We would also like
 666 to thank the anonymous reviewers for valuable suggestions which led to the
 667 improvement of the quality of this work.

668 References

- 669 [1] S. Q. Du, W. Yuan, [Mathematical modeling of interaction between innate](#)
 670 [and adaptive immune responses in COVID-19 and implications for viral](#)
 671 [pathogenesis](#), *Journal of Medical Virology* 92 (2020) 1615–1628.
 672 URL <https://onlinelibrary.wiley.com/doi/10.1002/jmv.25866>
- 673 [2] H. Harapan, N. Itoh, A. Yufika, W. Winardi, S. Keam, H. Te, D. Megawati,
 674 Z. Hayati, A. L. Wagner, M. Mudatsir, [Coronavirus disease 2019 \(covid-19\):](#)
 675 [A literature review](#), *Journal of infection and public health* 13 (5) (2020)
 676 667–673.
 677 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S1876034120304329)
 678 [S1876034120304329](https://www.sciencedirect.com/science/article/pii/S1876034120304329)
- 679 [3] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al, [Clinical features](#)
 680 [of patients infected with 2019 novel coronavirus in wuhan, china](#), *Lancet*
 681 395 (2020) 497–506.
 682 URL [https://doi.org/10.1016/S0140\0T1\textendash6736\(20](https://doi.org/10.1016/S0140\0T1\textendash6736(20)
 683 [30183\0T1\textendash5](https://doi.org/10.1016/S0140\0T1\textendash6736(20)

- 684 [4] C. Yang, J. Wang, *A mathematical model for the novel coronavirus*
685 *epidemic in wuhan, china*, *Mathematical Biosciences and Engineering* 17 (3)
686 (2020) 2708–2724.
687 URL [https://www.aimspress.com/fileOther/PDF/MBE/](https://www.aimspress.com/fileOther/PDF/MBE/mbe-17-03-148.pdf)
688 [mbe-17-03-148.pdf](https://www.aimspress.com/fileOther/PDF/MBE/mbe-17-03-148.pdf)
- 689 [5] World Health Organization, *Coronavirus* (2020).
690 URL [https://www.who.int/fr/health-topics/coronavirus/](https://www.who.int/fr/health-topics/coronavirus/coronavirus)
691 [coronavirus](https://www.who.int/fr/health-topics/coronavirus/coronavirus)
- 692 [6] M. Zhou, X. Zhang, J. Qu, *Coronavirus disease 2019 (COVID-*
693 *19): a clinical update*, *Frontiers of Medicine* (2020). doi:[https:](https://doi.org/10.1007/s11684-020-0767-8)
694 [//doi.org/10.1007/s11684-020-0767-8](https://doi.org/10.1007/s11684-020-0767-8).
695 URL [https://link.springer.com/content/pdf/10.1007/](https://link.springer.com/content/pdf/10.1007/s11684-020-0767-8.pdf)
696 [s11684-020-0767-8.pdf](https://link.springer.com/content/pdf/10.1007/s11684-020-0767-8.pdf)
- 697 [7] T. Li, C. Wei, W. Li, F. Hongwei, J. Shi, *Beijing union medical college*
698 *hospital on "pneumonia of novel coronavirus infection" diagnosis and*
699 *treatment proposal (v2.0)*, *Med J Peking Union Med Coll Hosp* (2020).
700 URL [http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.](http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html)
701 [002.html](http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html)
- 702 [8] M. O. Adewole, A. A. Onifade, F. A. Abdullah, F. Kasali, A. I. M. Ismail,
703 *Modeling the Dynamics of COVID-19 in Nigeria*, *Int. J. Appl. Comput.*
704 *Math.* 7 (3) (2021) 67. doi:[10.1007/s40819-021-01014-5](https://doi.org/10.1007/s40819-021-01014-5).
705 URL <https://doi.org/10.1007/s40819-021-01014-5>
- 706 [9] M. O. Adeniyi, S. I. Oke, M. I. Ekum, T. Benson, M. O. Adewole, *Assessing*
707 *the Impact of Public Compliance on the Use of Non-pharmaceutical Inter-*
708 *vention with Cost-Effectiveness Analysis on the Transmission Dynamics of*
709 *COVID-19: Insight from Mathematical Modeling*, Springer International
710 Publishing, Cham, 2022, pp. 579–618. doi:[10.1007/978-3-030-72834-2_](https://doi.org/10.1007/978-3-030-72834-2_17)
711 [17](https://doi.org/10.1007/978-3-030-72834-2_17).
712 URL https://doi.org/10.1007/978-3-030-72834-2_17
- 713 [10] P. Samui, J. Mondal, S. Khajanchi, *A mathematical model for COVID-19*
714 *transmission dynamics with a case study of India*, *Chaos Solitons & Fractals*
715 140 (2020) 110173, 11. doi:[10.1016/j.chaos.2020.110173](https://doi.org/10.1016/j.chaos.2020.110173).
716 URL <https://doi.org/10.1016/j.chaos.2020.110173>
- 717 [11] A. S. Bhadauria, R. Pathak, M. Chaudhary, *A SIQ mathematical model on*
718 *COVID-19 investigating the lockdown effect*, *Infectious Disease Modelling* 6
719 (2021) 244–257.
720 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S2468042721000014)
721 [S2468042721000014](https://www.sciencedirect.com/science/article/pii/S2468042721000014)
- 722 [12] M. Bachar, M. A. Khamsi, M. Bounkhel, *A mathematical model for the*
723 *spread of COVID-19 and control mechanisms in Saudi Arabia*, *Adv. Differ-*
724 *ence Equ.* (2021) Paper No. 253, 18doi:[10.1186/s13662-021-03410-z](https://doi.org/10.1186/s13662-021-03410-z).
725 URL <https://doi.org/10.1186/s13662-021-03410-z>

- 726 [13] N. I. Okposo, M. O. Adewole, E. N. Okposo, H. I. Ojarikre, F. A. Abdullah,
727 [A mathematical study on a fractional COVID-19 transmission model within](#)
728 [the framework of nonsingular and nonlocal kernel](#), Chaos Solitons Fractals
729 152 (2021) Paper No. 111427. doi:10.1016/j.chaos.2021.111427.
730 URL <https://doi.org/10.1016/j.chaos.2021.111427>
- 731 [14] M. O. Adewole, A. P. Okekunle, I. A. Adeoye, O. M. Akpa, [Investigating](#)
732 [the transmission dynamics of SARS-CoV-2 in Nigeria: A SEIR modelling](#)
733 [approach](#), Scientific African 15 (2022) e01116.
734 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S2468227622000254?via%3Dihub)
735 [S2468227622000254?via%3Dihub](https://www.sciencedirect.com/science/article/pii/S2468227622000254?via%3Dihub)
- 736 [15] G. González-Parra, A. J. Arenas, [Qualitative analysis of a mathematical](#)
737 [model with presymptomatic individuals and two SARS-CoV-2 variants](#),
738 Comput. Appl. Math. 40 (6) (2021) Paper No. 199, 25. doi:10.1007/
739 [s40314-021-01592-6](#).
740 URL <https://doi.org/10.1007/s40314-021-01592-6>
- 741 [16] T. S. Faniran, E. A. Bakare, A. O. Falade, [The COVID-19 model with](#)
742 [partially recovered carriers](#), J. Appl. Math. (2021) Art. ID 6406274, 17doi:
743 [10.1155/2021/6406274](#).
744 URL <https://doi.org/10.1155/2021/6406274>
- 745 [17] T. S. Faniran, A. Ali, N. E. Al-Hazmi, J. K. K. Asamoah, T. A. Nofal, M. O.
746 Adewole, [New variant of SARS-CoV-2 dynamics with imperfect vaccine](#),
747 Complexity 2022 (2022) Article ID 1062180.
748 URL <https://www.hindawi.com/journals/complexity/2022/1062180/>
- 749 [18] J. Mondal, S. Khajanchi, [Mathematical modeling and optimal intervention](#)
750 [strategies of the COVID-19 outbreak](#), Nonlinear dynamics 109 (2022)
751 177–202.
752 URL [https://europepmc.org/backend/ptpmcrender.fcgi?accid=](https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8801045&blobtype=pdf)
753 [PMC8801045&blobtype=pdf](https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8801045&blobtype=pdf)
- 754 [19] Z. S. Kifle, L. L. Obsu, [Mathematical modeling for COVID-19 transmission](#)
755 [dynamics: A case study in ethiopia](#), Results in Physics 34 (2022) 448–456.
756 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S2211379722000122)
757 [S2211379722000122](https://www.sciencedirect.com/science/article/pii/S2211379722000122)
- 758 [20] A. E. S. Almcera, G. Quiroz, E. A. Hernandez-Vargas, [Stability analysis in](#)
759 [COVID-19 within-host model with immune response](#), Commun. Nonlinear
760 Sci. Numer. Simul. 95 (2021) Paper No. 105584, 15. doi:10.1016/j.cnsns.
761 [2020.105584](#).
762 URL <https://doi.org/10.1016/j.cnsns.2020.105584>
- 763 [21] C. Li, J. Xu, J. Liu, Y. Zhou, [The within-host viral kinetics of SARS-CoV-2](#),
764 Math. Biosci. Eng. 17 (4) (2020) 2853–2861. doi:10.3934/mbe.2020159.
765 URL <https://doi.org/10.3934/mbe.2020159>

- 766 [22] B. J. Nath, K. Dehingia, V. N. Mishra, Y.-M. Chu, H. K. Sarmah, [Mathematical analysis of a within-host model of SARS-CoV-2](#), *Adv. Difference*
 767 *Equ.* (2021) Paper No. 113, 11doi:10.1186/s13662-021-03276-1.
 768 URL <https://doi.org/10.1186/s13662-021-03276-1>
 769
- 770 [23] I. Ghosh, *Within host dynamics of sars-cov-2 in humans: Modeling immune*
 771 *responses and antiviral treatments*, *SN Computer Science* 2 (2021).
- 772 [24] N. K. Vaidya, A. Bloomquist, A. S. Perelson, [Modeling within-host dynamics](#)
 773 [of SARS-CoV-2 infection: A case study in ferrets](#), *Viruses* 13 (8) (2021)
 774 1635.
 775 URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402735/>
- 776 [25] N. Heitzman-Breen, S. M. Ciupe, [Modeling within-host and aerosol](#)
 777 [dynamics of SARS-CoV-2: The relationship with infectiousness](#), *PLoS*
 778 *Computational Biology* 18 (8) (2022) e1009997.
 779 URL [https://journals.plos.org/ploscompbiol/article?id=10.](https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009997)
 780 [1371/journal.pcbi.1009997](https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009997)
- 781 [26] W. Garira, D. Mathebula, R. Netshikweta, [A mathematical modelling](#)
 782 [framework for linked within-host and between-host dynamics for infections](#)
 783 [with free-living pathogens in the environment](#), *Math. Biosci.* 256 (2014)
 784 58–78. doi:10.1016/j.mbs.2014.08.004.
 785 URL <https://doi.org/10.1016/j.mbs.2014.08.004>
- 786 [27] C. Chiyaka, W. Garira, S. Dube, [Transmission model of endemic human](#)
 787 [malaria in a partially immune population](#), *Math. Comput. Modelling* 46 (5-
 788 6) (2007) 806–822. doi:10.1016/j.mcm.2006.12.010.
 789 URL <https://doi.org/10.1016/j.mcm.2006.12.010>
- 790 [28] Z. Feng, J. Velasco-Hernandez, B. Tapia-Santos, [A mathematical model](#)
 791 [for coupling within-host and between-host dynamics in an environmentally-](#)
 792 [driven infectious disease](#), *Math. Biosci.* 241 (1) (2013) 49–55. doi:10.1016/
 793 [j.mbs.2012.09.004](#).
 794 URL <https://doi.org/10.1016/j.mbs.2012.09.004>
- 795 [29] D. A. Bundy, B. T. Grenfell, P. Rajagopalan, [Immunoepidemiology of lym-](#)
 796 [phatic filariasis: the relationship between infection and disease](#), *Parasitology*
 797 *Today* 7 (3) (1991) 71–75.
 798 URL [https://doi.org/10.1016/0169-4758\(91\)90038-P](https://doi.org/10.1016/0169-4758(91)90038-P)
- 799 [30] H. M. Yang, [Malaria transmission model for different levels of acquired](#)
 800 [immunity and temperature-dependent parameters \(vector\)](#), *Revista de*
 801 *saude publica* 34 (2000) 223–231.
 802 URL [https://www.scielo.br/j/rsp/a/ccLrLgyDmvvfxCfRSmcsvSP/](https://www.scielo.br/j/rsp/a/ccLrLgyDmvvfxCfRSmcsvSP/?lang=en)
 803 [?lang=en](https://www.scielo.br/j/rsp/a/ccLrLgyDmvvfxCfRSmcsvSP/?lang=en)
- 804 [31] N. Mideo, S. Alizon, T. Day, [Linking within- and between-host](#)
 805 [dynamics in the evolutionary epidemiology of infectious dis-](#)
 806 [eases](#), *Trends in Ecology and Evolution* 23 (9) (2008) 511–517.

- 807 doi:<https://doi.org/10.1016/j.tree.2008.05.009>.
 808 URL <https://www.sciencedirect.com/science/article/abs/pii/S0169534708002188#:~:text=The%20within%2Dhost%20dynamics%20will,might%20then%20alter%20inoculum%20size>.
 809
 810
- 811 [32] N. Bellomo, D. Burini, N. Outada, [Multiscale models of COVID-19 with mutations and variants](#), *Netw. Heterog. Media* 17 (3) (2022) 293–310. doi:
 812 [10.3934/nhm.2022008](https://doi.org/10.3934/nhm.2022008).
 813 URL <https://doi.org/10.3934/nhm.2022008>
 814
- 815 [33] N. Bellomo, R. Bingham, M. A. J. Chaplain, G. Dosi, G. Forni, D. A. Knopoff, J. Lowengrub, R. Twarock, M. E. Virgillito, [A multiscale model of virus pandemic: heterogeneous interactive entities in a globally connected world](#), *Math. Models Methods Appl. Sci.* 30 (8) (2020) 1591–1651. doi:
 816 [10.1142/S0218202520500323](https://doi.org/10.1142/S0218202520500323).
 817 URL <https://doi.org/10.1142/S0218202520500323>
 818
 819
 820
- 821 [34] X. Wang, S. Wang, J. Wang, L. Rong, [A multiscale model of COVID-19 dynamics](#), *Bull. Math. Biol.* 84 (9) (2022) Paper No. 99, 41. doi:
 822 [10.1007/s11538-022-01058-8](https://doi.org/10.1007/s11538-022-01058-8).
 823 URL <https://doi.org/10.1007/s11538-022-01058-8>
 824
- 825 [35] X. Zhang, Z. Ruan, M. Zheng, J. Zhou, S. Boccaletti, B. Barzel, [Epidemic spreading under mutually independent intra- and inter-host pathogen evolution](#), *Nature Communications* 13 (2022) 6218.
 826 URL <https://www.nature.com/articles/s41467-022-34027-9>
 827
 828
- 829 [36] E. J. Moore, S. Sirisubtawee, S. Koonprasert, [A Caputo-Fabrizio fractional differential equation model for HIV/AIDS with treatment compartment](#), *Adv. Difference Equ.* (2019) Paper No. 200, 20doi:[10.1186/s13662-019-2138-9](https://doi.org/10.1186/s13662-019-2138-9).
 830 URL <https://doi.org/10.1186/s13662-019-2138-9>
 831
 832
 833
- 834 [37] M. Caputo, M. Fabrizio, [A new definition of fractional derivative without singular kernel](#), *Progr. Fract. Differ. Appl.* 1 (2) (2015) 73–85.
 835 URL <http://www.naturalspublishing.com/files/published/Ogb83k287mo759.pdf>
 836
 837
- 838 [38] P. C. Doherty, S. J. Turner, R. G. Webby, P. G. Thomas, [Influenza and the challenge for immunology](#), *Nature Immunology* 7 (5) (2006) 449–455.
 839 URL <https://www.nature.com/articles/ni1343>
 840
- 841 [39] G. Li, Y. Fan, Y. Lai, T. Han, Z. Li, P. Zhou, P. Pan, W. Wang, D. Hu, X. Liu, Q. Zhang, J. Wu, [Coronavirus infections and immune responses](#), *Journal of Medical Virology* 92 (2020) 424–432.
 842 URL <https://onlinelibrary.wiley.com/doi/10.1002/jmv.25685>
 843
 844
- 845 [40] T. Uchiyama, D. L. Nelson, T. A. Fleisher, T. A. Waldmann, [A monoclonal antibody \(anti-Tac\) reactive with activated and functionally mature human](#)
 846

- 347 T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells,
 348 suppressor cells, and on one of two types of helper T cells., *The Journal of*
 349 *Immunology* 126 (4) (1981) 1398–1403.
- 350 [41] B. J. Meckiff, C. Ramírez-Suástegui, V. Fajardo, S. J. Chee, A. Kusnadi,
 351 H. Simon, S. Eschweiler, A. Grifoni, E. Pelosi, D. Weiskopf, A. Sette, F. Ay,
 352 G. Seumois, C. H. Ottensmeier, P. Vijayanand, Imbalance of regulatory and
 353 cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19, *Cell* 183 (5)
 354 (2020) 1340–1353.
- 355 [42] B. Alberts, A. Johnson, J. Lewis, et al., [The adaptive immune system](#), in:
 356 *Molecular Biology of the Cell*, 4th Edition, New York: Garland Science,
 357 2002, Ch. 24.
 358 URL <https://www.ncbi.nlm.nih.gov/books/NBK21070/>
- 359 [43] H. Lodish, A. Berk, C. A. Kaiser, M. Krieger, M. P. Scott, A. Bretsher,
 360 H. Ploegh, P. Matsudaira, *Molecular Cell Biology*, W. H. Freeman and
 361 Company, 2008.
- 362 [44] D. Bhavnani, E. R. James, K. E. Johnson, S. Beaudenon-Huibregtse,
 363 P. Chang, P. J. Rathouz, M. Weldon, A. Matouschek, A. E. Young, [Sars-cov-2 viral load is associated with risk of transmission to household and community contacts](#), *BMC Infectious Diseases* 22 (2022) 672.
 364
 365 URL <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07663-1>
 366
 367
- 368 [45] S. Marzban, R. Han, N. Juhász, G. Röst, A hybrid PDE–ABM model
 369 for viral dynamics with application to SARS-CoV-2 and influenza, *Royal*
 370 *Society Open Science* 8 (2021).
- 371 [46] Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. Leung,
 372 E. H. Lau, J. Y. Wong, X. Xing, N. Xiang, Y. Wu, C. Li, Q. Chen, D. Li,
 373 T. Liu, J. Zhao, M. Liu, W. Tu, C. Chen, L. Jin, R. Yang, Q. Wang, S. Zhou,
 374 R. Wang, H. Liu, Y. Luo, Y. Liu, G. Shao, H. Li, Z. Tao, Y. Yang, Z. Deng,
 375 B. Liu, Z. Ma, Y. Zhang, G. Shi, T. T. Lam, J. T. Wu, G. F. Gao, B. J.
 376 Cowling, B. Yang, G. M. Leung, Z. Feng, [Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia](#), *The New England*
 377 *Journal of Medicine* (2020).
 378
 379 URL <https://www.nejm.org/doi/10.1056/NEJMoa2001316>
- 380 [47] B. Alberts, A. Johnson, J. Lewis, et al., [Helper T cells and lymphocyte activation](#), in:
 381 *Molecular Biology of the Cell*, 4th Edition, New York:
 382 Garland Science, 2002, Ch. 24.
 383 URL <https://www.ncbi.nlm.nih.gov/books/NBK26827/>
- 384 [48] J. Wang, C. Kaperak, T. Sato, A. Sakuraba, COVID-19 reinfection: a rapid
 385 systematic review of case reports and case series, *Journal of Investigative*
 386 *Medicine* 69.

- 887 [49] S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith,
888 et al., [The incubation period of coronavirus disease 2019 \(COVID-19\) from](#)
889 [publicly reported confirmed cases: Estimation and application](#), *Ann Intern*
890 *Med* 172 (9) (2020) 577–582.
891 URL [https://annals.org/aim/fullarticle/2762808/
892 incubation-period-coronavirus-disease-2019-covid-19-from-publicly-reported](https://annals.org/aim/fullarticle/2762808/incubation-period-coronavirus-disease-2019-covid-19-from-publicly-reported)
- 893 [50] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, et al., [Substantial](#)
894 [undocumented infection facilitates the rapid dissemination of novel](#)
895 [coronavirus \(SARS-CoV-2\)](#), *Science* 368 (6490) (2020) 489–493.
896 URL [https://science.sciencemag.org/content/368/6490/489/
897 tab-pdf](https://science.sciencemag.org/content/368/6490/489/tab-pdf)
- 898 [51] E. A. Iboi, O. Sharomi, C. N. Ngonghala, A. B. Gumel, [Mathematical](#)
899 [modeling and analysis of COVID-19 pandemic in Nigeria](#), *Math. Biosci.*
900 *Eng.* 17 (6) (2020) 7192–7220. doi:10.3934/mbe.2020369.
901 URL <https://doi.org/10.3934/mbe.2020369>
- 902 [52] N. M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie,
903 M. Baguelin, et al., [Impact of non-pharmaceutical interventions \(NPIs\)](#)
904 [to reduce COVID-19 mortality and healthcare demand](#), Imperial College
905 London (16-03-2020)doi:<https://doi.org/10.25561/77482>.
906 URL [https://www.imperial.ac.uk/media/
907 imperial-college/medicine/sph/ide/gida-fellowships/
908 Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf](https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf)
- 909 [53] B. Tang, N. L. Bragazzi, Q. Li, S. Tang, Y. Xiao, J. Wu, [An up-](#)
910 [dated estimation of the risk of transmission of the novel coron-](#)
911 [avirus \(2019-nCoV\)](#), *Infectious Disease Modelling* 5 (2020) 248–255.
912 doi:<https://doi.org/10.1016/j.idm.2020.02.001>.
913 URL [https://www.sciencedirect.com/science/article/pii/
914 S246804272030004X](https://www.sciencedirect.com/science/article/pii/S246804272030004X)
- 915 [54] GITHUB[link].
916 URL <https://github.com/MoH-Malaysia/covid19-public>
- 917 [55] World Health Organization (WHO), webpage: www.who.org.
- 918 [56] C. Li, J. Xu, J. Liu, Y. Zhou, [The within-host viral kinetics of SARS-](#)
919 [CoV-2](#), *Mathematical Biosciences and Engineering* 17 (4) (2020) 2853–2861.
920 doi:10.3934/mbe.2020159.
921 URL <https://doi.org/10.3934/mbe.2020159>
- 922 [57] S. M. E. K. Chowdhury, J. T. Chowdhury, S. F. Ahmed, P. Agarwal, I. A.
923 Badruddin, S. Kamangar, [Mathematical modelling of COVID-19 disease](#)
924 [dynamics: interaction between immune system and SARS-CoV-2 within](#)
925 [host](#), *AIMS Math.* 7 (2) (2022) 2618–2633. doi:10.3934/math.2022147.
926 URL <https://doi.org/10.3934/math.2022147>

- 927 [58] R. Ben-Shachar, K. Koelle, [Minimal within-host dengue models highlight](#)
928 [the specific roles of the immune response in primary and secondary dengue](#)
929 [infections](#), *J. Royal Soc. Interface* 12 (103) (2015) 20140886.
930 URL [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305404/pdf/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305404/pdf/rsif20140886.pdf)
931 [rsif20140886.pdf](#)
- 932 [59] V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor, P. A. S., [Nonlinear dynamics](#)
933 [of immunogenic tumors: Parameter estimation and global bifurcation](#)
934 [analysis](#), *Bulletin of Mathematical Biology* 56 (2) (1994) 295–321.
935 URL [https://www.sciencedirect.com/science/article/abs/pii/](https://www.sciencedirect.com/science/article/abs/pii/S0092824005802605)
936 [S0092824005802605](#)
- 937 [60] L. G. de Pillis, W. Gu, A. E. Radunskaya, [Mixed immunotherapy and](#)
938 [chemotherapy of tumors: modeling, applications and biological interpre-](#)
939 [tations](#), *J. Theoret. Biol.* 238 (4) (2006) 841–862. doi:10.1016/j.jtbi.
940 2005.06.037.
941 URL <https://doi.org/10.1016/j.jtbi.2005.06.037>
- 942 [61] H. C. S. Karita, T. Q. D. Dong, C. Johnston, K. M. Neuzil, M. K.
943 Paasche-Orlow, P. J. Kissinger, A. Bershteyn, L. E. Thorpe, M. Deming,
944 A. Kottkamp, M. Laufer, R. J. Landovitz, A. Luk, R. Hoffman, P. Roy-
945 choudhury, C. A. Magaret, A. L. Greninger, M.-L. Huang, K. R. Jerome,
946 M. Wener, C. Celum, H. Y. Chu, J. M. Baeten, A. Wald, R. V. Barnabas,
947 E. R. Brown, [Trajectory of viral rna load among persons with incident](#)
948 [SARS-CoV-2 G614 infection \(Wuhan strain\) in association with COVID-19](#)
949 [symptom onset and severity](#), *JAMA Network Open* 5 (1) (2022) e2142796.
950 URL [https://jamanetwork.com/journals/jamanetworkopen/](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787768)
951 [fullarticle/2787768](#)
- 952 [62] J. Losada, J. J. Nieto, [Properties of a new fractional derivative without](#)
953 [singular kernel](#), *Progr. Fract. Differ. Appl.* 1 (2) (2015) 87–92.
954 URL [http://www.naturalspublishing.com/files/published/](http://www.naturalspublishing.com/files/published/2j1ns3h8o2s789.pdf)
955 [2j1ns3h8o2s789.pdf](#)
- 956 [63] I. L. Correa-Escudero, J. F. Gómez-Aguilar, M. G. López-López,
957 V. Alvarado-Martínez, D. Baleanu, [Correcting dimensional mismatch](#)
958 [in fractional models with power, exponential and proportional kernel:](#)
959 [Application to electrical systems](#), *Results in Physics* 40 (2022) 105867.
960 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S2211379722005083?via%3Dihub)
961 [S2211379722005083?via%3Dihub](#)
- 962 [64] H. Li, J. Cheng, H.-B. Li, S.-M. Zhong, [Stability analysis of a fractional-order](#)
963 [linear system described by the caputo–fabrizio derivative](#), *Mathematics* 7 (2)
964 (2019) 200.
965 URL <https://www.mdpi.com/2227-7390/7/2/200>
- 966 [65] A. D. Polyanin, A. V. Manzhirov, *Handbook of mathematics for engineers*
967 *and scientists*, Chapman & Hall/CRC, Boca Raton, FL, 2007.

- 968 [66] K. K.-W. To, O. T.-Y. Tsang, W.-S. Leung, A. R. Tam, T.-C. Wu, D. C.
 969 Lung, C. C.-Y. Yip, J.-P. Cai, J. M.-C. Chan, T. S.-H. Chik, D. P.-L. Lau,
 970 C. Y.-C. Choi, L.-L. Chen, W.-M. Chan, K.-H. Chan, J. D. Ip, A. C.-K. Ng,
 971 R. W.-S. Poon, C.-T. Luo, V. C.-C. Cheng, J. F.-W. Chan, I. F.-N. Hung,
 972 Z. Chen, H. Chen, K.-Y. Yuen, Temporal profiles of viral load in posterior
 973 oropharyngeal saliva samples and serum antibody responses during infection
 974 by sars-cov-2: an observational cohort study, *Lancet Infect Dis* 20 (5) (2020)
 975 565–574. doi:10.1016/S1473-3099(20)30196-1.
- 976 [67] MathWorks, <https://www.mathworks.com/help/optim/ug/lsqcurvefit.html>.
- 977 [68] A. Saltelli, M. Ratto, T. Andres, F. Campolongo, J. Cariboni, D. Gatelli,
 978 et al., Global sensitivity analysis. The primer, John Wiley & Sons, Ltd.,
 979 Chichester, 2008.
- 980 [69] S. Hoops, R. Hontecillas, V. Abedi, A. Leber, C. Philipson, A. Carbo,
 981 J. Bassaganya-Riera, Ordinary differential equations (ODEs) based
 982 modeling, in: *Computational Immunology: Models and Tools*, Elsevier,
 983 2016, Ch. 5, pp. 63–78.
 984 URL [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/B9780128036976000059)
 985 [B9780128036976000059](https://www.sciencedirect.com/science/article/pii/B9780128036976000059)
- 986 [70] S. Razavi, H. V. Gupta, What do we mean by sensitivity analysis? the
 987 need for comprehensive characterization of “global” sensitivity in earth and
 988 environmental systems models, *Water Resources Research* 51 (5) (2015)
 989 3070–3092.
 990 URL [https://agupubs.onlinelibrary.wiley.com/doi/10.1002/](https://agupubs.onlinelibrary.wiley.com/doi/10.1002/2014WR016527)
 991 [2014WR016527](https://agupubs.onlinelibrary.wiley.com/doi/10.1002/2014WR016527)
- 992 [71] N. Chitnis, J. M. Hyman, J. M. Cushing, Determining important pa-
 993 rameters in the spread of malaria through the sensitivity analysis of a
 994 mathematical model, *Bull. Math. Biol.* 70 (5) (2008) 1272–1296. doi:
 995 10.1007/s11538-008-9299-0.
 996 URL <https://doi.org/10.1007/s11538-008-9299-0>
- 997 [72] S. Marino, I. B. Hogue, C. J. Ray, D. E. Kirschner, A methodology for
 998 performing global uncertainty and sensitivity analysis in systems biology, *J.*
 999 *Theoret. Biol.* 254 (1) (2008) 178–196. doi:10.1016/j.jtbi.2008.04.011.
 1000 URL <https://doi.org/10.1016/j.jtbi.2008.04.011>
- 1001 [73] S. M. Blower, H. Dowlatabadi, Sensitivity and uncertainty analysis of
 1002 complex-models of disease transmission—an hiv model, as an example, *Int.*
 1003 *Stat. Rev.* 62 (1994) 229–243.
 1004 URL [https://mysite.science.uottawa.ca/rsmith43/mat4996/](https://mysite.science.uottawa.ca/rsmith43/mat4996/blower_lhsmethodology.pdf)
 1005 [blower_lhsmethodology.pdf](https://mysite.science.uottawa.ca/rsmith43/mat4996/blower_lhsmethodology.pdf)
- 1006 [74] A. Atangana, K. M. Owolabi, New numerical approach for fractional differ-
 1007 ential equations, *Math. Model. Nat. Phenom.* 13 (1) (2018) Paper No. 3,

- 1008 21. doi:10.1051/mmnp/2018010.
1009 URL <https://doi.org/10.1051/mmnp/2018010>
- 1010 [75] S. Deinhardt-Emmer, S. Böttcher, C. Häring, L. Giebeler, A. Henke, R. Zell,
1011 J. Jungwirth, P. M. Jordan, O. Werz, F. Hornung, C. Brandt, M. Marquet,
1012 A. S. Mosig, M. W. Pletz, M. Schacke, R. Rödel, Jürgen Heller, S. Nietzsche,
1013 B. Löffler, C. Ehrhardt, [SARS-CoV-2 causes severe epithelial inflammation](#)
1014 [and barrier dysfunction](#), Journal of virology 95 (10) (2021) e00110–21.
1015 URL <https://journals.asm.org/doi/pdf/10.1128/JVI.00110-21>
- 1016 [76] COVID19 Vaccine Tracker (2021). [link].
1017 URL <https://covid19.trackvaccines.org/country/nigeria/>
- 1018 [77] Centers for Disease Control and Prevention,
1019 [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html)
1020 [ncov/vaccines/keythingstoknow.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html).
1021 URL [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html)
1022 [keythingstoknow.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html)
- 1023 [78] NHS, [https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-](https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/)
1024 [vaccination/coronavirus-vaccine/](https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/).
1025 URL [https://www.nhs.uk/conditions/coronavirus-covid-19/](https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/)
1026 [coronavirus-vaccination/coronavirus-vaccine/](https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/)
- 1027 [79] M. Martcheva, N. Tuncer, C. St Mary, [Coupling within-host and between-](#)
1028 [host infectious diseases models](#), Biomath 42 (2015) 1510091.
1029 URL [https://people.clas.ufl.edu/maia/files/](https://people.clas.ufl.edu/maia/files/WHBHREVv6-BIOMATH-R.pdf)
1030 [WHBHREVv6-BIOMATH-R.pdf](https://people.clas.ufl.edu/maia/files/WHBHREVv6-BIOMATH-R.pdf)

Conceptualization, M.O.A.; methodology, M.O.A. and T.S.F.; software, M.O.A. and F.A.A and M.K.M.A.; validation, M.O.A. and F.A.A and M.K.M.A.; formal analysis, M.O.A.; investigation, M.O.A. and T.S.F. and F.A.A. and M.K.M.A.; resources, M.O.A. and F.A.A and M.K.M.A.; data curation, M.O.A.; writing—original draft preparation, M.O.A. and T.S.F.; writing—review and editing, M.O.A. and F.A.A and M.K.M.A.; supervision, F.A.A and M.K.M.A.; project administration, F.A.A.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof